SARS-CoV-2 mRNA vaccine design enabled by prototyp

Nature

586, 567-571

DOI: 10.1038/s41586-020-2622-0

Citation Report

#	Article	IF	Citations
1	A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature, 2020, 586, 560-566.	13.7	527
2	Impaired natural killer cell counts and cytolytic activity in patients with severe COVID-19. Blood Advances, 2020, 4, 5035-5039.	2.5	92
3	A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice. Cell, 2020, 183, 1070-1085.e12.	13.5	472
4	Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. New England Journal of Medicine, 2020, 383, 2427-2438.	13.9	1,242
5	Coronavirus disease-19 vaccine development utilizing promising technology. Current Opinion in HIV and AIDS, 2020, 15, 351-358.	1.5	4
6	Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. Npj Vaccines, 2020, 5, 91.	2.9	286
7	Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies. Immunobiology, 2020, 225, 152008.	0.8	65
8	SARS-CoV-2 vaccines in development. Nature, 2020, 586, 516-527.	13.7	1,659
9	New insights on possible vaccine development against SARS-CoV-2. Life Sciences, 2020, 260, 118421.	2.0	8
10	Warp Speed for Coronavirus Disease 2019 (COVID-19) Vaccines: Why Are Children Stuck in Neutral?. Clinical Infectious Diseases, 2021, 73, 336-340.	2.9	70
11	Principles Learned from the International Race to Develop a Safe and Effective COVID-19 Vaccine. ACS Central Science, 2020, 6, 1341-1347.	5.3	11
12	Immune-mediated approaches against COVID-19. Nature Nanotechnology, 2020, 15, 630-645.	15.6	260
13	Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. EBioMedicine, 2020, 62, 103132.	2.7	77
14	SARS-CoV-2 mRNA Vaccines Foster Potent Antigen-Specific Germinal Center Responses Associated with Neutralizing Antibody Generation. Immunity, 2020, 53, 1281-1295.e5.	6.6	285
15	Antibody-guided structure-based vaccines. Seminars in Immunology, 2020, 50, 101428.	2.7	29
16	A facile method of mapping HIV-1 neutralizing epitopes using chemically masked cysteines and deep sequencing. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29584-29594.	3.3	5
17	A Thermostable mRNA Vaccine against COVID-19. Cell, 2020, 182, 1271-1283.e16.	13.5	485
18	Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. New England Journal of Medicine, 2020, 383, 1544-1555.	13.9	936

#	Article	IF	Citations
19	Immunological strategies against spike protein: Neutralizing antibodies and vaccine development for COVIDâ€19. Clinical and Translational Medicine, 2020, 10, e184.	1.7	8
20	A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone. Scientific Reports, 2020, 10, 18149.	1.6	90
21	Concanavalin A targetingN-linked glycans in spike proteins influence viral interactions. Dalton Transactions, 2020, 49, 13538-13543.	1.6	10
22	The Current Status of COVID-19 Vaccines. Frontiers in Genome Editing, 2020, 2, 579297.	2.7	25
23	Inhibition of Coronavirus Entry In Vitro and Ex Vivo by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. MBio, 2020, 11, .	1.8	63
24	The SARS-CoV-2 Spike Glycoprotein Biosynthesis, Structure, Function, and Antigenicity: Implications for the Design of Spike-Based Vaccine Immunogens. Frontiers in Immunology, 2020, 11, 576622.	2.2	317
25	Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2. Cell, 2020, 183, 1367-1382.e17.	13.5	420
26	A Review of the Progress and Challenges of Developing a Vaccine for COVID-19. Frontiers in Immunology, 2020, 11, 585354.	2.2	384
27	Neurological injuries in COVID-19 patients: direct viral invasion or a bystander injury after infection of epithelial/endothelial cells. Journal of NeuroVirology, 2020, 26, 631-641.	1.0	38
28	Immunological considerations for COVID-19 vaccine strategies. Nature Reviews Immunology, 2020, 20, 615-632.	10.6	806
29	Cell and animal models of SARS-CoV-2 pathogenesis and immunity. DMM Disease Models and Mechanisms, 2020, 13, .	1.2	46
30	Mitigating Coronavirus Induced Dysfunctional Immunity for At-Risk Populations in COVID-19: Trained Immunity, BCG and â€œNew Old Friendsâ€• Frontiers in Immunology, 2020, 11, 2059.	2.2	18
31	A Scalable Topical Vectored Vaccine Candidate against SARS-CoV-2. Vaccines, 2020, 8, 472.	2.1	20
32	Harnessing Recent Advances in Synthetic DNA and Electroporation Technologies for Rapid Vaccine Development Against COVID-19 and Other Emerging Infectious Diseases. Frontiers in Medical Technology, 2020, 2, 571030.	1.3	29
33	Vaccines for COVID-19. Clinical and Experimental Immunology, 2020, 202, 162-192.	1.1	185
34	SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates. Emerging Microbes and Infections, 2020, 9, 2076-2090.	3.0	53
35	The HMOX1 Pathway as a Promising Target for the Treatment and Prevention of SARS-CoV-2 of 2019 (COVID-19). International Journal of Molecular Sciences, 2020, 21, 6412.	1.8	28
36	Development of vaccines and antivirals for combating viral pandemics. Nature Biomedical Engineering, 2020, 4, 1128-1133.	11.6	66

#	Article	IF	Citations
37	A Potential Peptide From Soy Cheese Produced Using Lactobacillus delbrueckii WS4 for Effective Inhibition of SARS-CoV-2 Main Protease and S1 Glycoprotein. Frontiers in Molecular Biosciences, 2020, 7, 601753.	1.6	39
38	RNA Vaccines: A Suitable Platform for Tackling Emerging Pandemics?. Frontiers in Immunology, 2020, 11, 608460.	2.2	54
39	A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. Vaccines, 2020, 8, 771.	2.1	61
40	Current Prevention of COVID-19: Natural Products and Herbal Medicine. Frontiers in Pharmacology, 2020, 11, 588508.	1.6	99
41	Threading the Pieces Together: Integrative Perspective on SARS-CoV-2. Pathogens, 2020, 9, 912.	1.2	6
42	COVID-19 Vaccines Currently under Preclinical and Clinical Studies, and Associated Antiviral Immune Response. Vaccines, 2020, 8, 649.	2.1	42
43	COVID-19 Vaccines: â€œWarp Speedâ€•Needs Mind Melds, Not Warped Minds. Journal of Virology, 2020, 94, .	1.5	79
44	Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination. Life Sciences, 2020, 257, 118056.	2.0	175
45	Design of a highly thermotolerant, immunogenic SARS-CoV-2 spike fragment. Journal of Biological Chemistry, 2021, 296, 100025.	1.6	43
46	SARSâ€CoVâ€2 replicating in nonprimate mammalian cells probably have critical advantages for COVIDâ€19 vaccines due to antiâ€Gal antibodies: A minireview and proposals. Journal of Medical Virology, 2021, 93, 351-356.	2.5	13
47	Severe acute respiratory syndromeâ€coronavirusâ€2 spike (S) protein based vaccine candidates: State of the art and future prospects. Reviews in Medical Virology, 2021, 31, e2183.	3.9	43
48	GESS: a database of global evaluation of SARS-CoV-2/hCoV-19 sequences. Nucleic Acids Research, 2021, 49, D706-D714.	6.5	65
49	Learning from the past: development of safe and effective COVID-19 vaccines. Nature Reviews Microbiology, 2021, 19, 211-219.	13.6	126
50	T cell immunity to SARS-CoV-2 following natural infection and vaccination. Biochemical and Biophysical Research Communications, 2021, 538, 211-217.	1.0	88
51	New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine, 2021, 39, 197-201.	1.7	67
52	Review of registered clinical trials for the treatment of COVIDâ€19. Drug Development Research, 2021, 82, 474-493.	1.4	26
53	Nucleic Acid-Based Technologies Targeting Coronaviruses. Trends in Biochemical Sciences, 2021, 46, 351-365.	3.7	35
54	D614G Spike Mutation Increases SARS CoV-2 Susceptibility to Neutralization. Cell Host and Microbe, 2021, 29, 23-31.e4.	5.1	308

#	Article	IF	Citations
55	Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines. Advanced Functional Materials, 2021, 31, 2008352.	7.8	25
56	Functional importance of the D614G mutation in the SARS-CoV-2 spike protein. Biochemical and Biophysical Research Communications, 2021, 538, 108-115.	1.0	79
57	COVID-19: A review of therapeutic strategies and vaccine candidates. Clinical Immunology, 2021, 222, 108634.	1.4	180
58	Vaccine formulations in clinical development for the prevention of severe acute respiratory syndrome coronavirus 2 infection. Advanced Drug Delivery Reviews, 2021, 169, 168-189.	6.6	62
59	COVID-19: The Effect of Host Genetic Variations on Hostâ€“Virus Interactions. Journal of Proteome Research, 2021, 20, 139-153.	1.8	14
60	Viral targets for vaccines against COVID-19. Nature Reviews Immunology, 2021, 21, 73-82.	10.6	832
61	RNA therapeutics for retinal diseases. Expert Opinion on Biological Therapy, 2021, 21, 603-613.	1.4	15
62	DNA vaccines against COVID-19: Perspectives and challenges. Life Sciences, 2021, 267, 118919.	2.0	172
63	Identifying and repurposing antiviral drugs against severe acute respiratory syndrome coronavirus 2 with in silico and inÂvitro approaches. Biochemical and Biophysical Research Communications, 2021, 538, 137-144.	1.0	12
64	A guide to vaccinology: from basic principles to new developments. Nature Reviews Immunology, 2021, 21, 83-100.	10.6	709
65	Hybridization Networks of mRNA and Branched RNA Hybrids. ChemBioChem, 2021, 22, 924-930.	1.3	2
66	A Cytometrist's Guide to Coordinating and Performing Effective COVID â€19 Research. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2021, 99, 11-18.	1.1	2
67	Live unattenuated vaccines for controlling viral diseases, including COVIDâ€19. Journal of Medical Virology, 2021, 93, 1943-1949.	2.5	4
68	The rapidly evolving role of cryo-EM in drug design. Drug Discovery Today: Technologies, 2020, 38, 91-102.	4.0	19
69	Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses. Vaccines, 2021, 9, 73.	2.1	24
70	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. Emerging Microbes and Infections, 2021, 10, 342-355.	3.0	37
71	An Update on Self-Amplifying mRNA Vaccine Development. Vaccines, 2021, 9, 97.	2.1	117
72	Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity. Nature Communications, 2021, 12, 324.	5.8	79

#	Article	IF	Citations
74	Gamma irradiation-mediated inactivation of enveloped viruses with conservation of genome integrity: Potential application for SARS-CoV-2 inactivated vaccine development. Open Life Sciences, 2021, 16, 558-570.	0.6	8
75	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946.	3.0	11
77	An update to â€œnovel therapeutic approaches for treatment of COVID-19â€• Journal of Molecular Medicine, 2021, 99, 303-310.	1.7	22
78	A Single Immunization with Spike-Functionalized Ferritin Vaccines Elicits Neutralizing Antibody Responses against SARS-CoV-2 in Mice. ACS Central Science, 2021, 7, 183-199.	5.3	134
80	Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications. Journal of Biomedical Science, 2021, 28, 9.	2.6	167
81	Cell fusion as a link between the SARS-CoV-2 spike protein, COVID-19 complications, and vaccine side effects. Oncotarget, 2021, 12, 2476-2488.	0.8	7
83	Promising Extracellular Vesicle-Based Vaccines against Viruses, Including SARS-CoV-2. Biology, 2021, 10, 94.	1.3	43
85	Preclinical Study of DNA Vaccines Targeting SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	0
87	A human cell-based SARS-CoV-2 vaccine elicits potent neutralizing antibody responses and protects mice from SARS-CoV-2 challenge. Emerging Microbes and Infections, 2021, 10, 1555-1573.	3.0	6
88	D614G Mutation Alters SARS-CoV-2 Spike Conformation and Enhances Protease Cleavage at the S1/S2 Junction. Cell Reports, 2021, 34, 108630.	2.9	263
89	Vaccine Development and Immune Responses in COVID-19: Lessons from the Past. , 2021, , 149-185.		1
91	Vaccines, Resource Allocation, and Unproven Treatments. , 2021, , 151-174.		0
92	Advancements in mRNA Encoded Antibodies for Passive Immunotherapy. Vaccines, 2021, 9, 108.	2.1	34
93	mRNA vaccines for COVID-19: what, why and how. International Journal of Biological Sciences, 2021, 17, 1446-1460.	2.6	185
94	SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut, 2021, 70, 635-640.	6.1	173
95	SARS-CoV-2: vaccines in the pandemic era. Military Medical Research, 2021, 8, 1.	1.9	104
96	Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans. Vaccines, 2021, 9, 61.	2.1	105
97	Promoting versatile vaccine development for emerging pandemics. Npj Vaccines, 2021, 6, 26.	2.9	26

#	Article	IF	Citations
99	Biosecurity risks associated with vaccine platform technologies. Vaccine, 2022, 40, 2514-2523.	1.7	9
100	The Key Role of Nucleic Acid Vaccines for One Health. Viruses, 2021, 13, 258.	1.5	19
101	A lymph nodeâ€“targeted Amphiphile vaccine induces potent cellular and humoral immunity to SARS-CoV-2. Science Advances, 2021, 7, .	4.7	38
102	Gastrodin Inhibits Virus Infection by Promoting the Production of Type I Interferon. Frontiers in Pharmacology, 2020, 11, 608707.	1.6	8
103	COVID-19 mRNA vaccines. Journal of Genetics and Genomics, 2021, 48, 107-114.	1.7	59
104	SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond. Vaccines, 2021, 9, 147.	2.1	175
105	mRNA vaccine: a potential therapeutic strategy. Molecular Cancer, 2021, 20, 33.	7.9	188
106	Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response. Vaccine, 2021, 39, 1241-1247.	1.7	22
108	A Scoping Insight on Potential Prophylactics, Vaccines and Therapeutic Weaponry for the Ongoing Novel Coronavirus (COVID-19) Pandemic- A Comprehensive Review. Frontiers in Pharmacology, 2020, 11, 590154.	1.6	8
111	BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature, 2021, 592, 283-289.	13.7	494
112	COVID-19 Vaccines (Revisited) and Oral-Mucosal Vector System as a Potential Vaccine Platform. Vaccines, 2021, 9, 171.	2.1	43
113	DNA-launched RNA replicon vaccines induce potent anti-SARS-CoV-2 immune responses in mice. Scientific Reports, 2021, 11, 3125.	1.6	17
114	SARS-CoV-2 virus: Vaccines in development. Fundamental Research, 2021, 1, 131-138.	1.6	12
115	Immunogenicity and Neutralizing Activity Comparison of SARS-CoV-2 Spike Full-Length and Subunit Domain Proteins in Young Adult and Old-Aged Mice. Vaccines, 2021, 9, 316.	2.1	11
116	Does COVID-19 Vaccination Warrant the Classical Principle â€œofelein i mi vlaptinâ€?. Medicina (Lithuania), 2021, 57, 253.	0.8	10
117	Self-assembled mRNA vaccines. Advanced Drug Delivery Reviews, 2021, 170, 83-112.	6.6	248
118	Nanoparticle-Mediated Cytoplasmic Delivery of MessengerÂRNA Vaccines: Challenges and Future Perspectives. Pharmaceutical Research, 2021, 38, 473-478.	1.7	63
119	Conformational Changes of the Receptor Binding Domain of SARS-CoV-2 Spike Protein and Prediction of a B-Cell Antigenic Epitope Using Structural Data. Frontiers in Artificial Intelligence, 2021, 4, 630955.	2.0	13

#	Article	IF	Citations
120	Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 2021, 33, 521-527.	1.8	19
121	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Frontiers in Immunology, 2021, 12, 657711.	2.2	50
122	Animal Hosts and Experimental Models of SARS-CoV-2 Infection. Chemotherapy, 2021, 66, 1-9.	0.8	13
123	Why would a Black man volunteer for a government-funded science experiment?. EClinicalMedicine, 2021, 33, 100788.	3.2	0
124	SARS-CoV-2 mutations in MHC-I-restricted epitopes evade CD8 ⁺ T cell responses. Science Immunology, 2021, 6, .	5.6	143
125	COVID-19 vaccines: rapid development, implications, challenges and future prospects. Human Cell, 2021, 34, 711-733.	1.2	227
127	DNA vaccine candidate encoding SARS-CoV-2 spike proteins elicited potent humoral and Th1 cell-mediated immune responses in mice. PLoS ONE, 2021, 16, e0248007.	1.1	32
128	RNA-based therapies: A cog in the wheel of lung cancer defense. Molecular Cancer, 2021, 20, 54.	7.9	53
130	One or two injections of MVA-vectored vaccine shields hACE2 transgenic mice from SARS-CoV-2 upper and lower respiratory tract infection. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	60
132	mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. Science, 2021, 372, 1413-1418.	6.0	468
133	Chargeâ€Conversion Strategies for Nucleic Acid Delivery. Advanced Functional Materials, 2021, 31, 2011103.	7.8	17
134	How to Face the Advent of SARS-CoV-2 Vaccination in IBD Patients: Another Task for Gastroenterologists. Vaccines, 2021, 9, 248.	2.1	0
135	Viral Mimicry as a Design Template for Nucleic Acid Nanocarriers. Frontiers in Chemistry, 2021, 9, 613209.	1.8	9
137	Soluble Spike DNA Vaccine Provides Long-Term Protective Immunity against SARS-CoV-2 in Mice and Nonhuman Primates. Vaccines, 2021, 9, 307.	2.1	28
138	Correlates of Vaccine-Induced Protection against SARS-CoV-2. Vaccines, 2021, 9, 238.	2.1	49
139	The nextâ€generation coronavirusÂdiagnostic techniques with particular emphasis on the SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 4219-4241.	2.5	7
140	Advances in vaccine delivery systems against viral infectious diseases. Drug Delivery and Translational Research, 2021, 11, 1401-1419.	3.0	19
141	The COVID-19 mRNA Vaccines and the Pandemic: Do They Represent the Beginning of the End or the End of the Beginning?. Clinical Therapeutics, 2021, 43, 549-556.	1.1	13

#	Article	IF	Citations
142	Developmental Status of the Potential Vaccines for the Mitigation of the COVID-19 Pandemic and a Focus on the Effectiveness of the Pfizer-BioNTech and Moderna mRNA Vaccines. Current Clinical Microbiology Reports, 2021, 8, 178-185.	1.8	46
143	Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development. Lancet, The, 2021, 397, 1229-1236.	6.3	54
144	Therapeutic RNA Delivery for COVID and Other Diseases. Advanced Healthcare Materials, 2021, 10, e2002022.	3.9	31
147	Novel approaches for vaccine development. Cell, 2021, 184, 1589-1603.	13.5	145
148	Profiles of current COVID-19 vaccines. Wiener Klinische Wochenschrift, 2021, 133, 271-283.	1.0	32
150	Potent Neutralization Antibodies Induced by a Recombinant Trimeric Spike Protein Vaccine Candidate Containing PIKA Adjuvant for COVID-19. Vaccines, 2021, 9, 296.	2.1	6
151	COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice. Journal of Virology, 2021, 95, .	1.5	78
152	Perspectives on RNA Vaccine Candidates for COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 635245.	1.6	44
153	A Comprehensive Review of the Global Efforts on COVID-19 Vaccine Development. ACS Central Science, 2021, 7, 512-533.	5.3	217
154	Preclinical efficacy and safety analysis of gamma-irradiated inactivated SARS-CoV-2 vaccine candidates. Scientific Reports, 2021, 11, 5804.	1.6	15
155	Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Science Advances, 2021, 7, .	4.7	100
159	How to Understand Herd Immunity in the Context of COVID-19. Viral Immunology, 2021, 34, 174-181.	0.6	17
160	An Updated Review of SARS-CoV-2 Vaccines and the Importance of Effective Vaccination Programs in Pandemic Times. Vaccines, 2021, 9, 433.	2.1	85
161	COVID-19 immunity and vaccines: what a pharmacist needs to know. Asian Biomedicine, 2021, 15, 51-67.	0.2	0
162	Introduction of Two Prolines and Removal of the Polybasic Cleavage Site Lead to Higher Efficacy of a Recombinant Spike-Based SARS-CoV-2 Vaccine in the Mouse Model. MBio, 2021, 12, .	1.8	62
163	SARS-CoV-2 vaccines: A critical perspective through efficacy data and barriers to herd immunity. Respiratory Medicine, 2021, 180, 106355.	1.3	25
166	A novel linker-immunodominant site (LIS) vaccine targeting the SARS-CoV-2 spike protein protects against severe COVID-19 in Syrian hamsters. Emerging Microbes and Infections, 2021, 10, 874-884.	3.0	11
167	Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273. Journal of Pharmacy Practice, 2022, 35, 947-951.	0.5	82

#	Article	IF	Citations
169	Safe and effective two-in-one replicon-and-VLP minispike vaccine for COVID-19: Protection of mice after a single immunization. PLoS Pathogens, 2021, 17, e1009064.	2.1	21
170	Safety and immunogenicity of the SARS-CoV-2 BNT162b1 mRNA vaccine in younger and older Chinese adults: a randomized, placebo-controlled, double-blind phase 1 study. Nature Medicine, 2021, 27, 1062-1070.	15.2	114
172	COVID-19 Vaccines: Current Understanding on Immunogenicity, Safety, and Further Considerations. Frontiers in Immunology, 2021, 12, 669339.	2.2	81
173	Pharmaceutical Aspects and Clinical Evaluation of COVID-19 Vaccines. Immunological Investigations, 2021, 50, 743-779.	1.0	16
174	mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents. Npj Vaccines, 2021, 6, 57.	2.9	118
175	Innate and adaptive immune responses toward nanomedicines. Acta Pharmaceutica Sinica B, 2021, 11, 852-870.	5.7	26
176	N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. Cell, 2021, 184, 2332-2347.e16.	13.5	784
177	Immunogenicity and efficacy of mRNA COVID-19 vaccine MRT5500 in preclinical animal models. Npj Vaccines, 2021, 6, 61.	2.9	66
178	Potential 3â€chymotrypsinâ€like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVIDâ€19 vaccine and drug development. FASEB Journal, 2021, 35, e21573.	0.2	18
179	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. ACS Nano, 2021, 15, 5793-5818.	7.3	32
180	Better, Faster, Stronger: mRNA Vaccines Show Promise for Influenza Vaccination in Older Adults. Immunological Investigations, 2021, 50, 810-820.	1.0	10
181	Protective Efficacy of Inactivated Vaccine against SARS-CoV-2 Infection in Mice and Non-Human Primates. Virologica Sinica, 2021, 36, 879-889.	1.2	17
182	SARSâ€'CoV-2 RBD219-N1C1: A yeast-expressed SARS-CoV-2 recombinant receptor-binding domain candidate vaccine stimulates virus neutralizing antibodies and T-cell immunity in mice. Human Vaccines and Immunotherapeutics, 2021, 17, 2356-2366.	1.4	64
185	Path to Success and Future Impact of Nucleic Acid Vaccines: DNA and mRNA. Molecular Frontiers Journal, 2021, 05, 38-57.	0.9	6
186	A narrative review of COVID-19: magnesium isoglycyrrhizinate as a potential adjuvant treatment. Annals of Palliative Medicine, 2021, 10, 4777-4798.	0.5	9
187	Progress in research on the S protein as the target of COVID-19 vaccines. Expert Review of Vaccines, 2021, 20, 769-772.	2.0	6
188	IgM and IgG Immunoreactivity of SARS-CoV-2 Recombinant M Protein. International Journal of Molecular Sciences, 2021, 22, 4951.	1.8	20
190	Multifunctional Immunoadjuvants for Use in Minimalist Nucleic Acid Vaccines. Pharmaceutics, 2021, 13, 644.	2.0	17

#	Article	IF	Citations
192	Immune response induced by oral administration with a Saccharomyces cerevisiae-based SARS-CoV-2 vaccine in mice. Microbial Cell Factories, 2021, 20, 95.	1.9	23
193	MoiRNAiFold: a novel tool for complex in silico RNA design. Nucleic Acids Research, 2021, 49, 4934-4943.	6.5	9
195	Thrombotic Thrombocytopenia after COVID-19 Vaccination: In Search of the Underlying Mechanism. Vaccines, 2021, 9, 559.	2.1	64
197	Protein Expression Correlates Linearly with mRNA Dose over Up to Five Orders of Magnitude In Vitro and In Vivo. Biomedicines, 2021, 9, 511.	1.4	7
198	Thermostability, Tunability, and Tenacity of RNA as Rubbery Anionic Polymeric Materials in Nanotechnology and Nanomedicineâ€"Specific Cancer Targeting with Undetectable Toxicity. Chemical Reviews, 2021, 121, 7398-7467.	23.0	45
200	The COVIDâ€19 Menace. Global Challenges, 2021, 5, 2100004.	1.8	5
201	CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nature Medicine, 2021, 27, 1280-1289.	15.2	365
202	COVIDâ€19: vaccineâ€™s progress. Microbial Biotechnology, 2021, 14, 1246-1257.	2.0	16
203	Brief review on repurposed drugs and vaccines for possible treatment of COVID-19. European Journal of Pharmacology, 2021, 898, 173977.	1.7	29
204	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. Advanced Drug Delivery Reviews, 2021, 172, 314-338.	6.6	75
205	The current landscape of nucleic acid therapeutics. Nature Nanotechnology, 2021, 16, 630-643.	15.6	578
206	Non-Immunotherapy Application of LNP-mRNA: Maximizing Efficacy and Safety. Biomedicines, 2021, 9, 530.	1.4	54
207	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. International Reviews of Immunology, 2021, , 1-16.	1.5	6
211	Interaction of small molecules with the SARS-CoV-2 papain-like protease: In silico studies and inÂvitro validation of protease activity inhibition using an enzymatic inhibition assay. Journal of Molecular Graphics and Modelling, 2021, 104, 107851.	1.3	29
214	A network analysis of COVID-19 mRNA vaccine patents. Nature Biotechnology, 2021, 39, 546-548.	9.4	58
216	A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccine. Vaccine, 2021, 39, 2791-2799.	1.7	185
217	Landscape of epitopes targeted by TÂcells in 852 individuals recovered from COVID-19: Meta-analysis, immunoprevalence, and web platform. Cell Reports Medicine, 2021, 2, 100312.	3.3	44
218	A core-shell structured COVID-19 mRNA vaccine with favorable biodistribution pattern and promising immunity. Signal Transduction and Targeted Therapy, 2021, 6, 213.	7.1	76

#	Article	IF	Citations
219	The dawn of mRNA vaccines: The COVID-19 case. Journal of Controlled Release, 2021, 333, 511-520.	4.8	276
220	Structure-Based and Rational Design of a Hepatitis C Virus Vaccine. Viruses, 2021, 13, 837.	1.5	7
221	Cellular and Humoral Immune Responses in Mice Immunized with Vaccinia Virus Expressing the SARS-CoV-2 Spike Protein. Journal of Immunology, 2021, 206, 2596-2604.	0.4	4
222	Identification of a Direct-Acting Antiviral Agent Targeting RNA Helicase via a Graphene Oxide Nanobiosensor. ACS Applied Materials & Interfaces, 2021, 13, 25715-25726.	4.0	7
224	Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of mRNA-1273 Vaccine Recipients. Clinical Infectious Diseases, 2022, 74, 715-718.	2.9	141
225	Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization. Communications Biology, 2021, 4, 597.	2.0	35
226	Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants. Genes and Diseases, 2022, 9, 216-229.	1.5	28
228	Messenger RNA expressing PfCSP induces functional, protective immune responses against malaria in mice. Npj Vaccines, 2021, 6, 84.	2.9	52
229	The Immunopathobiology of SARS-CoV-2 Infection. FEMS Microbiology Reviews, 2021, 45, .	3.9	9
230	Vaccine Considerations for Multiple Sclerosis in the COVID-19 Era. Advances in Therapy, 2021, 38, 3550-3588.	1.3	23
231	Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection. Science Translational Medicine, 2021, 13, .	5.8	198
233	Science at Its Best in the Time of the COVID-19 Pandemic. ACS Infectious Diseases, 2021, 7, 2209-2210.	1.8	3
234	Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2ÂS for viral entry. Molecular Therapy, 2021, 29, 1984-2000.	3.7	19
235	Tools and Techniques for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)/COVID-19 Detection. Clinical Microbiology Reviews, 2021, 34, .	5.7	205
236	Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. Journal of Allergy and Clinical Immunology, 2021, 147, 2075-2082.e2.	1.5	117
237	Low-dose single-shot COVID-19 mRNA vaccines lie ahead. Molecular Therapy, 2021, 29, 1944-1945.	3.7	5
238	The Status and Prospects of Epsteinâ€“Barr Virus Prophylactic Vaccine Development. Frontiers in Immunology, 2021, 12, 677027.	2.2	23
239	Immunological Approaches to the Treatment of Novel Coronavirus Infection (Review). Sovremennye Tehnologii V Medicine, 2021, 13, 81.	0.4	4

#	Article	IF	Citations
240	An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose. Vaccine, 2021, 39, 3745-3755.	1.7	9
241	Stabilization of the SARS-CoV-2 Spike Receptor-Binding Domain Using Deep Mutational Scanning and Structure-Based Design. Frontiers in Immunology, 2021, 12, 710263.	2.2	32
242	Updates on the coronavirus disease 2019 vaccine and consideration in children. Clinical and Experimental Pediatrics, 2021, 64, 328-338.	0.9	8
243	Measles, mumps, rubella prevention: how can we do better?. Expert Review of Vaccines, 2021, 20, 811-826.	2.0	13
244	Nasal vaccination against SARS-CoV-2: Synergistic or alternative to intramuscular vaccines?. International Journal of Pharmaceutics, 2021, 603, 120686.	2.6	83
245	Advances in Neutralization Assays for SARSâ€CoVâ€2. Scandinavian Journal of Immunology, 2021, 94, e13088.	1.3	40
246	Emerging Advances of Nanotechnology in Drug and Vaccine Delivery against Viral Associated Respiratory Infectious Diseases (VARID). International Journal of Molecular Sciences, 2021, 22, 6937.	1.8	20
247	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. Science, 2021, 373, .	6.0	318
248	Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines. Vaccines, 2021, 9, 708.	2.1	51
249	Vaccine allergy: evidence to consider for COVID-19 vaccines. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 401-409.	1.1	32
250	Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design. Briefings in Functional Genomics, 2021, 20, 289-303.	1.3	16
251	Animal models for SARS-CoV-2. Current Opinion in Virology, 2021, 48, 73-81.	2.6	52
252	Mice with induced pulmonary morbidities display severe lung inflammation and mortality following exposure to SARS-CoV-2. JCI Insight, 2021, 6, .	2.3	7
253	Structure-function relations of the SARS-CoV-2 spike protein and impact of mutations in the variants of concern. Comptes Rendus - Biologies, 2021, 344, 77-110.	0.1	4
255	Evaluation of serological lateral flow assays for severe acute respiratory syndrome coronavirus-2. BMC Infectious Diseases, 2021, 21, 580.	1.3	20
256	A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice. Molecular Therapy, 2021, 29, 1970-1983.	3.7	111
257	Infection kinetics of Covid-19 and containment strategy. Scientific Reports, 2021, 11, 11606.	1.6	6
258	A Murine CD8+ T Cell Epitope Identified in the Receptor-Binding Domain of the SARS-CoV-2 Spike Protein. Vaccines, 2021, 9, 641.	2.1	5

#	Article	IF	Citations
259	Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertension Research, 2021, 44, 1047-1053.	1.5	7
261	M2e-Based Influenza Vaccines with Nucleoprotein: A Review. Vaccines, 2021, 9, 739.	2.1	13
262	Site-Specific Steric Control of SARS-CoV-2 Spike Glycosylation. Biochemistry, 2021, 60, 2153-2169.	1.2	54
264	COVID-19 and earlier pandemics, sepsis, and vaccines: A historical perspective. Journal of Intensive Medicine, 2021, 1, 4-13.	0.8	9
265	Where to Next? Research Directions after the First Hepatitis C Vaccine Efficacy Trial. Viruses, 2021, 13, 1351.	1.5	1
266	COVID-19 vaccines: concerns beyond protective efficacy and safety. Expert Review of Vaccines, 2021, 20, 1013-1025.	2.0	56
267	Covid-19 Vaccine Benefits and Concerns: Nigerian Perspectives. Journal of Clinical and Medical Research, 0, , .	0.0	0
268	Early approval of COVID-19 vaccines: Pros and cons. Human Vaccines and Immunotherapeutics, 2021, 17, 3288-3296.	1.4	14
270	Functional binding dynamics relevant to the evolution of zoonotic spillovers in endemic and emergent Betacoronavirus strains. Journal of Biomolecular Structure and Dynamics, 2022, 40, 10978-10996.	2.0	7
271	SARS-CoV-2 and HIV-1 â€" a tale of two vaccines. Nature Reviews Immunology, 2021, 21, 543-544.	10.6	7
272	A single dose of the SARS-CoV-2 vaccine BNT162b2 elicits Fc-mediated antibody effector functions and TÂcell responses. Cell Host and Microbe, 2021, 29, 1137-1150.e6.	5.1	173
274	Functionalized DMP-039 Hybrid Nanoparticle as a Novel mRNA Vector for Efficient Cancer Suicide Gene Therapy. International Journal of Nanomedicine, 2021, Volume 16, 5211-5232.	3.3	24
275	The investigation of mRNA vaccines formulated in liposomes administrated in multiple routes against SARS-CoV-2. Journal of Controlled Release, 2021, 335, 449-456.	4.8	42
276	Potency of BNT162b2 and mRNAâ€1273 vaccineâ€induced neutralizing antibodies against severe acute respiratory syndromeâ€CoVâ€2 variants of concern: A systematic review of in vitro studies. Reviews in Medical Virology, 2022, 32, e2277.	3.9	57
277	Fast Development of High-Quality Vaccines in a Pandemic. Chest, 2021, 160, e1-e3.	0.4	3
278	Semi-enzymatic synthesis of pseudouridine. Bioorganic and Medicinal Chemistry Letters, 2021, 44, 128105.	1.0	5
279	Current Perspectives in the Discovery of Newer Medications Against the Outbreak of COVID-19. Frontiers in Molecular Biosciences, 2021, 8, 648232.	1.6	1
280	Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity. ACS Central Science, 2021, 7, 1368-1380.	5.3	21

#	Article	IF	Citations
281	A recombinant spike protein subunit vaccine confers protective immunity against SARS-CoV-2 infection and transmission in hamsters. Science Translational Medicine, 2021, 13, .	5.8	56
282	Response to mRNA vaccination for COVID-19 among patients with multiple myeloma. Leukemia, 2021, 35, 3534-3541.	3.3	71
283	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses, 2021, 13, 1397.	1.5	6
284	Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines. Vaccines, 2021, 9, 734.	2.1	89
285	SARS-CoV 2 spike protein S1 subunit as an ideal target for stable vaccines: A bioinformatic study. Materials Today: Proceedings, 2022, 49, 904-912.	0.9	14
287	The success of SARS-CoV-2 vaccines and challenges ahead. Cell Host and Microbe, 2021, 29, 1111-1123.	5.1	67
288	Hepatocyte Nuclear Factor 4 alpha 2 Messenger RNA Reprograms Liverâ€Enriched Transcription Factors and Functional Proteins in Endâ€Stage Cirrhotic Human Hepatocytes. Hepatology Communications, 2021, 5, 1911-1926.	2.0	7
289	Are We Paving the Way to Dig Out of the â€œPandemic Holeâ€? A Narrative Review on SARS-CoV-2 Vaccination: From Animal Models to Human Immunization. Medical Sciences (Basel, Switzerland), 2021, 9, 53.	1.3	1
290	Immunogenicity and Protective Efficacy of a Highly Thermotolerant, Trimeric SARS-CoV-2 Receptor Binding Domain Derivative. ACS Infectious Diseases, 2021, 7, 2546-2564.	1.8	34
291	Nanotechnologyâ€Assisted RNA Delivery: From Nucleic Acid Therapeutics to COVIDâ€19 Vaccines. Small Methods, 2021, 5, 2100402.	4.6	45
292	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules, 2021, 11, 993.	1.8	136
293	Multiple Sclerosis, Disease-Modifying Therapies and COVID-19: A Systematic Review on Immune Response and Vaccination Recommendations. Vaccines, 2021, 9, 773.	2.1	25
294	HIV and Messenger RNA Vaccine. Cureus, 2021, 13, e16197.	0.2	9
296	Neutralizing activity of Sputnik V vaccine sera against SARS-CoV-2 variants. Nature Communications, 2021, 12, 4598.	5.8	88
297	The role of micronutrient and immunomodulation effect in the vaccine era of COVID-19. Journal of the Chinese Medical Association, 2021, 84, 821-826.	0.6	19
298	Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. Nature Reviews Immunology, 2021, 21, 475-484.	10.6	434
299	Distinguishing features of current COVID-19 vaccines: knowns and unknowns of antigen presentation and modes of action. Npj Vaccines, 2021, 6, 104.	2.9	241
301	Cold atmospheric plasma: A non-negligible strategy for viral RNA inactivation to prevent SARS-CoV-2 environmental transmission. AIP Advances, 2021, 11, 085019.	0.6	9

#	Article	IF	Citations
302	Lessons Learnt From the COVID-19 Pandemic. Frontiers in Public Health, 2021, 9, 694705.	1.3	24
303	SARS-CoV-2 spike protein: pathogenesis, vaccines, and potential therapies. Infection, 2021, 49, 855-876.	2.3	61
304	Deliver the promise: RNAs as a new class of molecular entities for therapy and vaccination. , 2022, 230, 107967.		40
305	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50
306	Cationic Liposomes as Vectors for Nucleic Acid and Hydrophobic Drug Therapeutics. Pharmaceutics, 2021, 13, 1365.	2.0	61
307	NMR chemical shift assignments of RNA oligonucleotides to expand the RNA chemical shift database. Biomolecular NMR Assignments, 2021, 15, 479-490.	0.4	5
308	An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity. Vaccine, 2021, 39, 4988-5001.	1.7	26
309	Attenuated activation of pulmonary immune cells in mRNA-1273â€“vaccinated hamsters after SARS-CoV-2 infection. Journal of Clinical Investigation, 2021, 131, .	3.9	23
310	2021: an immunotherapy odyssey and the rise of nucleic acid nanotechnology. Nanomedicine, 2021, 16, 1635-1640.	1.7	12
311	COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. Immunity, 2021, 54, 1869-1882.e6.	6.6	59
313	Nanoparticles in the clinic: An update post <scp>COVID</scp>â€19 vaccines. Bioengineering and Translational Medicine, 2021, 6, e10246.	3.9	173
315	Accelerated COVID-19 vaccine development: milestones, lessons, and prospects. Immunity, 2021, 54, 1636-1651.	6.6	165
317	COVID-19: The Disease, the Immunological Challenges, the Treatment with Pharmaceuticals and Low-Dose Ionizing Radiation. Cells, 2021, 10, 2212.	1.8	4
318	An Update on mRNA-Based Viral Vaccines. Vaccines, 2021, 9, 965.	2.1	14
319	3D printing technologies forin vitrovaccine testing platforms and vaccine delivery systems against infectious diseases. Essays in Biochemistry, 2021, 65, 519-531.	2.1	2
320	Immunogenicity of Low-Dose Prime-Boost Vaccination of mRNA Vaccine CV07050101 in Non-Human Primates. Viruses, 2021, 13, 1645.	1.5	8
321	Evolutionary Tracking of SARS-CoV-2 Genetic Variants Highlights an Intricate Balance of Stabilizing and Destabilizing Mutations. MBio, 2021, 12, e0118821.	1.8	30
322	Cytidine acetylation yields a hypoinflammatory synthetic messenger RNA. Cell Chemical Biology, 2022, 29, 312-320.e7.	2.5	14

#	Article	IF	Citations
323	Yeast-produced RBD-based recombinant protein vaccines elicit broadly neutralizing antibodies and durable protective immunity against SARS-CoV-2 infection. Cell Discovery, 2021, 7, 71.	3.1	26
324	Challenges and Progress in Vaccine Development for COVID-19 Coronavirus (SARS-CoV-2): A Review. The Open Covid Journal, 2021, 1, 65-76.	0.4	0
325	The protective immunity induced by SARS-CoV-2 infection and vaccination: a critical appraisal. Exploration of Immunology, 2021, , 199-225.	1.7	5
326	mRNA vaccines for infectious diseases: principles, delivery and clinical translation. Nature Reviews Drug Discovery, 2021, 20, 817-838.	21.5	577
327	COMPUTER SIMULATION IN THE DEVELOPMENT OF VACCINES AGAINST COVID-19 BASED ON HLA-SYSTEM ANTIGENS. Journal of Clinical Practice, 0, , .	0.2	0
328	mRNA-1273 protects against SARS-CoV-2 beta infection in nonhuman primates. Nature Immunology, 2021, 22, 1306-1315.	7.0	57
330	Essential considerations during vaccine design against COVID-19 and review of pioneering vaccine candidate platforms. International Immunopharmacology, 2021, 97, 107679.	1.7	9
332	Nanotechnology-Enabled COVID-19 mRNA Vaccines. Encyclopedia, 2021, 1, 773-780.	2.4	12
333	Antigen Presentation of mRNA-Based and Virus-Vectored SARS-CoV-2 Vaccines. Vaccines, 2021, 9, 848.	2.1	64
334	Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. Journal of Virology, 2021, 95, e0131321.	1.5	89
335	Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	23
336	A Combination Adjuvant for the Induction of Potent Antiviral Immune Responses for a Recombinant SARS-CoV-2 Protein Vaccine. Frontiers in Immunology, 2021, 12, 729189.	2.2	23
337	Pseudouridines in RNAs: switching atoms means shifting paradigms. FEBS Letters, 2021, 595, 2310-2322.	1.3	13
338	A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. Journal of Virology, 2021, 95, e0059221.	1.5	11
339	Adaptive immune determinants of viral clearance and protection in mouse models of SARS-CoV-2. Science Immunology, 2021, 6, eabl4509.	5.6	141
341	Virusâ€Mimic mRNA Vaccine for Cancer Treatment. Advanced Therapeutics, 2021, 4, 2100144.	1.6	11
342	Development and preclinical evaluation of virusâ€like particle vaccine against COVIDâ€19 infection. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 258-270.	2.7	27
343	Early insight into antibody-dependent enhancement after SARS-CoV-2 mRNA vaccination. Human Vaccines and Immunotherapeutics, 2021, 17, 4121-4125.	1.4	3

#	Article	IF	Citations
344	Key points to keep in mind related to COVID-19 vaccines in people with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2021, 54, 103142.	0.9	1
345	The Present and Future of Yellow Fever Vaccines. Pharmaceuticals, 2021, 14, 891.	1.7	27
346	Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science, 2021, 373, eabj0299.	6.0	244
348	A universal bacteriophage T4 nanoparticle platform to design multiplex SARS-CoV-2 vaccine candidates by CRISPR engineering. Science Advances, 2021, 7, eabh1547.	4.7	44
349	The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice. Signal Transduction and Targeted Therapy, 2021, 6, 340.	7.1	48
350	Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency. Molecular and Cellular Toxicology, 2022, 18, 1-8.	0.8	73
351	Trivalent Subunit Vaccine Candidates for COVID-19 and Their Delivery Devices. Journal of the American Chemical Society, 2021, 143, 14748-14765.	6.6	48
352	Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches. MSystems, 2021, 6, e0038821.	1.7	10
353	Nanotechnology-empowered vaccine delivery for enhancing CD8+ T cells-mediated cellular immunity. Advanced Drug Delivery Reviews, 2021, 176, 113889.	6.6	48
354	Lipid-nanoparticle-encapsulated mRNA vaccines induce protective memory CD8 TÂcells against a lethal viral infection. Molecular Therapy, 2021, 29, 2769-2781.	3.7	20
355	Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. MBio, 2021, 12, e0190821.	1.8	32
356	Rapid measurement of SARS-CoV-2 spike T cells in whole blood from vaccinated and naturally infected individuals. Journal of Clinical Investigation, 2021, 131, .	3.9	89
357	Vaccinia virus-based vaccines confer protective immunity against SARS-CoV-2 virus in Syrian hamsters. PLoS ONE, 2021, 16, e0257191.	1.1	19
358	Humoral and cellular immunity and the safety of COVID-19 vaccines: a summary of data published by 21 May 2021. International Immunology, 2021, 33, 529-540.	1.8	28
359	Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines. Cell, 2021, 184, 5432-5447.e16.	13.5	131
360	Nucleic acid delivery for therapeutic applications. Advanced Drug Delivery Reviews, 2021, 178, 113834.	6.6	122
361	Chikungunya virus titration, detection and diagnosis using N-Acetylglucosamine (GlcNAc) specific lectin based virus capture assay. Virus Research, 2021, 302, 198493.	1.1	6
363	Synthetic modified messenger RNA for therapeutic applications. Acta Biomaterialia, 2021, 131, 1-15.	4.1	34

#	Article	IF	Citations
364	The Input of Structural Vaccinology in the Search for Vaccines against Bunyaviruses. Viruses, 2021, 13, 1766.	1.5	2
365	SARS-CoV-2 (Covid-19) vaccines structure, mechanisms and effectiveness: A review. International Journal of Biological Macromolecules, 2021, 188, 740-750.	3.6	83
366	SARS-CoV-2 S2P spike ages through distinct states with altered immunogenicity. Journal of Biological Chemistry, 2021, 297, 101127.	1.6	9
367	Thrombosis post COVID-19 vaccinations: Potential link to ACE pathways. Thrombosis Research, 2021, 206, 137-138.	0.8	1
368	Programmable technologies to manipulate gene expression at the RNA level. Current Opinion in Chemical Biology, 2021, 64, 27-37.	2.8	2
369	A Report on Myocarditis Adverse Events in the U.S. Vaccine Adverse Events Reporting System (VAERS) in Association with COVID-19 Injectable Biological Products. Current Problems in Cardiology, 2021, , 101011.	1.1	10
370	Immune response variables and viral mutations impact on COVID-19 reinfection and relapse. International Immunopharmacology, 2021, 100, 108108.	1.7	7
371	Animal models of SARS-CoV-2 and COVID-19 for the development of prophylactic and therapeutic interventions. , 2021, 228, 107931.		18
372	Determination of the denaturation temperature of the Spike protein S1 of SARS-CoV-2 (2019 nCoV) by Raman spectroscopy. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2022, 264, 120269.	2.0	7
373	pDNA and mRNA vaccines. , 2022, , 157-205.		1
374	The COVID-19 vaccine: A race nearing the finish line. Apollo Medicine, 2021, .	0.0	1
375	Lethal Human Coronavirus Infections and the Role of Vaccines in Their Prevention. , 2021, , 533-549.		1
376	Adjuvanted SARS-CoV-2 spike protein elicits neutralizing antibodies and CD4 T cell responses after a single immunization in mice. EBioMedicine, 2021, 63, 103197.	2.7	31
377	Current State of the First COVID-19 Vaccines. Vaccines, 2021, 9, 30.	2.1	64
379	Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages. Immune Network, 2021, 21, e4.	1.6	26
381	Immunological perspectives on the pathogenesis, diagnosis, prevention and treatment of COVID-19. Molecular Biomedicine, 2021, 2, 1.	1.7	20
382	Updates on Coronavirus Disease-2019 Vaccine and Consideration in Children. Pediatric Infection and Vaccine, 2021, 28, 7.	0.1	7
383	Nanomaterial Delivery Systems for mRNA Vaccines. Vaccines, 2021, 9, 65.	2.1	310

#	Article	IF	Citations
385	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. Journal of Experimental Medicine, 2021, 218, .	4.2	283
409	From Cold to Killer: How SARS-CoV-2 Evolved without Hemagglutinin Esterase to Agglutinate, Then Clot Blood Cells in Pulmonary and Systemic Microvasculature. SSRN Electronic Journal, 0, , .	0.4	4
410	Immunology of SARS-CoV-2 infections and vaccines. Advances in Immunology, 2021, 151, 49-97.	1.1	12
411	Nanotechnology-based approaches in the fight against SARS-CoV-2. AIMS Microbiology, 2021, 7, 368-398.	1.0	7
412	SARS-CoV-2: Pathogenic Mechanisms and Host Immune Response. Advances in Experimental Medicine and Biology, 2021, 1313, 99-134.	0.8	6
413	A Single Dose of a Hybrid hAdV5-Based Anti-COVID-19 Vaccine Induces a Long-Lasting Immune Response and Broad Coverage against VOC. Vaccines, 2021, 9, 1106.	2.1	5
414	Effectiveness of COVIDâ€'19 vaccines and their challenges (Review). Experimental and Therapeutic Medicine, 2021, 22, 1407.	0.8	23
415	Targeted Delivery of mRNA with One-Component Ionizable Amphiphilic Janus Dendrimers. Journal of the American Chemical Society, 2021, 143, 17975-17982.	6.6	48
416	A Modular Biomaterial Scaffoldâ€Based Vaccine Elicits Durable Adaptive Immunity to Subunit SARSâ€CoVâ€2 Antigens. Advanced Healthcare Materials, 2021, 10, e2101370.	3.9	10
417	Rapid development of analytical methods for evaluating pandemic vaccines: a COVID-19 perspective. Bioanalysis, 2021, 13, 1805-1826.	0.6	11
418	mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science, 2021, 374, abm0829.	6.0	609
420	Innovations and development of Covid-19 vaccines: A patent review. Journal of Infection and Public Health, 2022, 15, 123-131.	1.9	27
421	SARS-CoV-2 subunit vaccine adjuvants and their signaling pathways. Expert Review of Vaccines, 2022, 21, 69-81.	2.0	22
422	Helpful Lessons and Cautionary Tales: How Should COVID-19 Drug Development and Access Inform Approaches to Non-Pandemic Diseases?. American Journal of Bioethics, 2021, 21, 4-19.	0.5	20
423	Diverse vaccine platforms safeguarding against SARS-CoV-2 and its variants. Expert Review of Vaccines, 2022, 21, 47-67.	2.0	3
424	RNA-based therapeutics to treat human fungal infections. Trends in Microbiology, 2022, 30, 411-420.	3.5	14
425	Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs. Drug Metabolism and Pharmacokinetics, 2021, 41, 100424.	1.1	114
426	Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and TÂcell immune response against SARS-CoV-2 infection. Molecular Therapy, 2022, 30, 1885-1896.	3.7	16

#	Article	IF	Citations
427	Stabilized coronavirus spike stem elicits a broadly protective antibody. Cell Reports, 2021, 37, 109929.	2.9	64
429	Predicting Mutational Effects on Receptor Binding of the Spike Protein of SARS-CoV-2 Variants. Journal of the American Chemical Society, 2021, 143, 17646-17654.	6.6	39
431	Innovative vaccine platforms against infectious diseases: Under the scope of the COVID-19 pandemic. International Journal of Pharmaceutics, 2021, 610, 121212.	2.6	11
433	SARS-CoV-2 S1 Protein Induces Endolysosome Dysfunction and Neuritic Dystrophy. Frontiers in Cellular Neuroscience, 2021, 15, 777738.	1.8	7
434	COVID-19 mRNA vaccine allergy. Current Opinion in Pediatrics, 2021, 33, 610-617.	1.0	15
435	Broad-Spectrum and Gram-Negative-Targeting Antibiotics Differentially Regulate Antibody Isotype Responses to Injected Vaccines. Vaccines, 2021, 9, 1240.	2.1	3
437	Spike Glycoprotein Is Central to Coronavirus Pathogenesis-Parallel Between m-CoV and SARS-CoV-2. Annals of Neurosciences, 2021, 28, 201-218.	0.9	7
438	Sterilizing Immunity against COVID-19: Developing Helper T cells I and II activating vaccines is imperative. Biomedicine and Pharmacotherapy, 2021, 144, 112282.	2.5	10
440	Complete protection by a single-dose skin patchâ€“delivered SARS-CoV-2 spike vaccine. Science Advances, 2021, 7, eabj8065.	4.7	31
441	Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants. Vaccine, 2021, 39, 7001-7011.	1.7	20
442	Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity. Cells, 2021, 10, 2949.	1.8	26
443	Vaccination in the Philippines: experiences from history and lessons for the future. Human Vaccines and Immunotherapeutics, 2021, 17, 1873-1876.	1.4	4
444	Vaccines and Treatment of Coronavirus Disease 2019. Korean Journal of Medicine, 2020, 95, 364-369.	0.1	1
446	Principles for designing an optimal mRNA lipid nanoparticle vaccine. Current Opinion in Biotechnology, 2022, 73, 329-336.	3.3	102
447	SARS-CoV-2 Delta (B.1.617.2) Variant: A Unique T478K Mutation in Receptor Binding Motif (RBM) of Spike Gene. Immune Network, 2021, 21, e32.	1.6	51
449	Immunopathology and Immunopathogenesis of COVID-19, what we know and what we should learn. Gene Reports, 2021, 25, 101417.	0.4	15
450	Variant SARS-CoV-2 mRNA vaccines confer broad neutralization as primary or booster series in mice. Vaccine, 2021, 39, 7394-7400.	1.7	63
451	Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity, 2021, 54, 2877-2892.e7.	6.6	260

#	Article	IF	Citations
452	Probing Affinity, Avidity, Anticooperativity, and Competition in Antibody and Receptor Binding to the SARS-CoV-2 Spike by Single Particle Mass Analyses. ACS Central Science, 2021, 7, 1863-1873.	5.3	20
453	Self and Nonself Short Constituent Sequences of Amino Acids in the SARS-CoV-2 Proteome for Vaccine Development. Covid, 2021, 1, 555-574.	0.7	4
454	Recombinant protein subunit SARS-CoV-2 vaccines formulated with CoVaccine HTâ„¢ adjuvant induce broad, Th1 biased, humoral and cellular immune responses in mice. Vaccine: X, 2021, 9, 100126.	0.9	13
455	Performance Evaluation of Lateral Flow Assays for Coronavirus Disease-19 Serology. Clinics in Laboratory Medicine, 2022, 42, 31-56.	0.7	8
456	Killing Two Birds with One Stone by Administration of Soluble ACE2: A Promising Strategy to Treat Both Cardiovascular Diseases and SARS-CoV-2 Infection. Viruses, 2021, 13, 2243.	1.5	4
457	An Established Th2-Oriented Response to an Alum-Adjuvanted SARS-CoV-2 Subunit Vaccine Is Not Reversible by Sequential Immunization with Nucleic Acid-Adjuvanted Th1-Oriented Subunit Vaccines. Vaccines, 2021, 9, 1261.	2.1	10
459	The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines. Frontiers in Cell and Developmental Biology, 2021, 9, 789427.	1.8	100
460	Career advice from my father: â€œGo where you are lovedâ€• Molecular Biology of the Cell, 2021, 32, ae3.	0.9	0
462	Innovative recombinant protein-based vaccinesÂagainst SARS-CoV-2. , 2022, , 193-211.		1
463	A single dose, BCG-adjuvanted COVID-19 vaccine provides sterilising immunity against SARS-CoV-2 infection. Npj Vaccines, 2021, 6, 143.	2.9	47
464	Analysis of Glycosylation and Disulfide Bonding of Wild-Type SARS-CoV-2 Spike Glycoprotein. Journal of Virology, 2022, 96, JVI0162621.	1.5	24
465	COVIDâ€19 vaccinations: The unknowns, challenges, and hopes. Journal of Medical Virology, 2022, 94, 1336-1349.	2.5	75
466	A Mycobacteriophage-Based Vaccine Platform: SARS-CoV-2 Antigen Expression and Display. Microorganisms, 2021, 9, 2414.	1.6	6
467	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Vaccines, 2021, 9, 1345.	2.1	22
469	Non-propagative human parainfluenza virus type 2 nasal vaccine robustly protects the upper and lower airways against SARS-CoV-2. IScience, 2021, , 103379.	1.9	8
470	Multifunctional Dendronized Polypeptides for Controlled Adjuvanticity. Biomacromolecules, 2021, , .	2.6	5
471	Antisense oligonucleotide: A promising therapeutic option to beat COVID â€19. Wiley Interdisciplinary Reviews RNA, 2021, , e1703.	3.2	8
472	Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases. Clinical Microbiology Reviews, 2022, 35, e0012321.	5.7	10

#	Article	IF	Citations
473	Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies. Vaccines, 2021, 9, 1338.	2.1	17
474	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. Biomedicines, 2021, 9, 1740.	1.4	16
475	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. Seminars in Immunology, 2021, 55, 101533.	2.7	72
476	Nucleoside-Modified mRNA Vaccines Protect IFNAR ^{â€"/â€"} Mice against Crimean-Congo Hemorrhagic Fever Virus Infection. Journal of Virology, 2022, 96, JVI0156821.	1.5	24
477	Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines. Frontiers in Immunology, 2021, 12, 771242.	2.2	15
478	Strategies for induction of HIVâ€1 envelopeâ€reactive broadly neutralizing antibodies. Journal of the International AIDS Society, 2021, 24, e25831.	1.2	19
479	Polymers Strive for Accuracy: From Sequence-Defined Polymers to mRNA Vaccines against COVID-19 and Polymers in Nucleic Acid Therapeutics. Journal of the American Chemical Society, 2021, 143, 20529-20545.	6.6	16
480	Immunological Mechanisms of Vaccine-Induced Protection against SARS-CoV-2 in Humans. Immuno, 2021, 1, 442-456.	0.6	7
481	Mimicking the Biology of Engineered Protein and mRNA Nanoparticle Delivery Using a Versatile Microfluidic Platform. Pharmaceutics, 2021, 13, 1944.	2.0	4
482	Advances in mRNA and other vaccines against MERS-CoV. Translational Research, 2022, 242, 20-37.	2.2	11
485	Hookworm infection: Toward development of safe and effective peptide vaccines. Journal of Allergy and Clinical Immunology, 2021, 148, 1394-1419.e6.	1.5	2
486	Temporal variations in country-specific mutational profiles of SARS-CoV-2: effect on vaccine efficacy. Future Virology, 2021, 16, 805-819.	0.9	2
487	Chronic spontaneous urticaria after BNT162b2 mRNA (Pfizer-BioNTech) vaccination against SARS-CoV-2. Allergy and Asthma Proceedings, 2022, 43, 30-36.	1.0	31
488	Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies. Nanoscale, 2022, 14, 1054-1074.	2.8	22
489	Investigating Constraints Along the Plant Secretory Pathway to Improve Production of a SARS-CoV-2 Spike Vaccine Candidate. Frontiers in Plant Science, 2021, 12, 798822.	1.7	6
490	Sequencing SARS-CoV-2 genomes from saliva. Virus Evolution, 2022, 8, veab098.	2.2	4
491	Chemical modification of uridine modulates mRNA-mediated proinflammatory and antiviral response in primary human macrophages. Molecular Therapy - Nucleic Acids, 2022, 27, 854-869.	2.3	21
492	A structural view of the SARS-CoV-2 virus and its assembly. Current Opinion in Virology, 2022, 52, 123-134.	2.6	42

#	Article	IF	Citations
493	The cathelicidin CATH-2 efficiently neutralizes LPS- and E. coli-induced activation of porcine bone marrow derived macrophages. Veterinary Immunology and Immunopathology, 2022, 244, 110369.	0.5	5
494	Altered pre-existing SARS-CoV-2-specific T cell responses in elderly individuals. Clinical Immunology Communications, 2022, 2, 6-11.	0.5	6
495	Intranasal HD-Ad vaccine protects the upper and lower respiratory tracts of hACE2 mice against SARS-CoV-2. Cell and Bioscience, 2021, 11, 202.	2.1	13
497	Near-Infrared-Triggered Reversible Transformations of Gold Nanorod-Laden Lipid Assemblies: Implications for Cellular Delivery. ACS Applied Nano Materials, 2022, 5, 710-717.	2.4	2
498	From Bench to the Clinic: The Path to Translation of Nanotechnology-Enabled mRNA SARS-CoV-2 Vaccines. Nano-Micro Letters, 2022, 14, 41.	14.4	26
499	High-throughput and high-content bioassay enables tuning of polyester nanoparticles for cellular uptake, endosomal escape, and systemic in vivo delivery of mRNA. Science Advances, 2022, 8, eabk2855.	4.7	54
500	Cellular and humoral functional responses after BNT162b2 mRNA vaccination differ longitudinally between naive and subjects recovered from COVID-19. Cell Reports, 2022, 38, 110235.	2.9	35
501	A 2-month field cohort study of SARS-CoV-2 in saliva of BNT162b2 vaccinated nursing home workers. Communications Medicine, 2022, 2, .	1.9	12
503	Nasal prevention of SARS-CoV-2 infection by intranasal influenza-based boost vaccination in mouse models. EBioMedicine, 2022, 75, 103762.	2.7	32
504	Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents. Nature Communications, 2022, 13, 153.	5.8	45
505	Nuclear Magnetic Resonance Spectra and AMBER OL3 and ROC-RNA Simulations of UCUCGU Reveal Force Field Strengths and Weaknesses for Single-Stranded RNA. Journal of Chemical Theory and Computation, 2022, 18, 1241-1254.	2.3	11
506	Synthesis and Potential Applications of Lipid Nanoparticles in Medicine. Materials, 2022, 15, 682.	1.3	52
507	Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B. Science Advances, 2022, 8, eabj9815.	4.7	29
508	Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection. ELife, 2022, 11, .	2.8	19
509	Effectiveness of and Immune Responses to SARS-CoV-2 mRNA Vaccines and Their Mechanisms. Journal of Disaster Research, 2022, 17, 7-20.	0.4	2
510	mRNA Vaccines in the COVID-19 Pandemic and Beyond. Annual Review of Medicine, 2022, 73, 17-39.	5.0	120
511	Engineering synthetic RNA devices for cell control. Nature Reviews Genetics, 2022, 23, 215-228.	7.7	43
512	Review of Ribosome Interactions with SARS-CoV-2 and COVID-19 mRNA Vaccine. Life, 2022, 12, 57.	1.1	6

#	Article	IF	Citations
513	Identification and Tracking of Alloreactive T Cell Clones in Rhesus Macaques Through the RM-scTCR-Seq Platform. Frontiers in Immunology, 2021, 12, 804932.	2.2	7
514	A Comparative and Comprehensive Review of Antibody Applications in the Treatment of Lung Disease. Life, 2022, 12, 130.	1.1	1
515	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor binding domain vaccine in aged mice. Science Translational Medicine, 2022, 14, .	5.8	57
519	Population-Based Incidence of Guillain-BarrÃ© Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis. Frontiers in Immunology, 2022, 13, 782198.	2.2	5
520	Comparison of immune responses induced by two or three doses of an alumâ€adjuvanted inactivated SARSâ€CoVâ€2 vaccine in mice. Journal of Medical Virology, 2022, , .	2.5	4
521	Insight into the Advances in Clinical Trials of SARS-CoV-2 Vaccines. Canadian Journal of Infectious Diseases and Medical Microbiology, 2022, 2022, 1-16.	0.7	2
523	COVIDâ€19Â vaccination in patients receiving allergen immunotherapy (AIT) or biologicalsâ€"EAACI recommendations. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2313-2336.	2.7	12
524	Effects of SARSâ€CoVâ€2 mRNA vaccines on platelet polyphosphate levels and inflammation: A pilot study. Biomedical Reports, 2022, 16, 21.	0.9	4
527	Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. Npj Vaccines, 2021, 6, 153.	2.9	46
528	A third SARS-CoV-2 spike vaccination improves neutralization of variants-of-concern. Npj Vaccines, 2021, 6, 146.	2.9	14
529	A single intranasal dose of a live-attenuated parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in hamsters. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	43
531	Chimeric Fusion (F) and Attachment (G) Glycoprotein Antigen Delivery by mRNA as a Candidate Nipah Vaccine. Frontiers in Immunology, 2021, 12, 772864.	2.2	21
532	An aluminum hydroxide:CpG adjuvant enhances protection elicited by a SARS-CoV-2 receptor-binding domain vaccine in aged mice. Science Translational Medicine, 2021, , eabj5305.	5.8	4
533	Pre-Clinical Testing of Two Serologically Distinct Chimpanzee-Origin Adenovirus Vectors Expressing Spike of SARS-CoV-2. SSRN Electronic Journal, 0, , .	0.4	0
534	Biotechnology strategies for the development of novel therapeutics and vaccines against the novel COVID-19 pandemic. , 2022, , 205-226.		0
535	COVID-19 Vaccine: Between Myth and Truth. Vaccines, 2022, 10, 349.	2.1	12
536	Nanostructures for the Prevention, Diagnosis, and Treatment of SARS-CoV-2: A Review. ACS Applied Nano Materials, 2022, 5, 6029-6054.	2.4	12
537	T cell responses to SARS-CoV-2 in humans and animals. Journal of Microbiology, 2022, 60, 276-289.	1.3	8

#	Article	IF	Citations
538	Resurfaced ZIKV EDIII nanoparticle immunogens elicit neutralizing and protective responses inÂvivo. Cell Chemical Biology, 2022, 29, 811-823.e7.	2.5	6
539	COVID-19 Vaccines: An Overview of Different Platforms. Bioengineering, 2022, 9, 72.	1.6	32
540	Identification of a Potential mRNAâ€based Vaccine Candidate against the SARSâ€CoVâ€2 Spike Glycoprotein: A Reverse Vaccinology Approach. ChemistrySelect, 2022, 7, .	0.7	9
542	Lipid Nanoparticle Delivery Systems to Enable mRNA-Based Therapeutics. Pharmaceutics, 2022, 14, 398.	2.0	31
544	COVID-19 mRNA vaccines: Platforms and current developments. Molecular Therapy, 2022, 30, 1850-1868.	3.7	102
545	High-Titer Neutralizing Antibodies against the SARS-CoV-2 Delta Variant Induced by Alhydroxyquim-II-Adjuvanted Trimeric Spike Antigens. Microbiology Spectrum, 2022, 10, e0169521.	1.2	8
546	Genetic variants of COVID-19 and vaccination. Is there a Correlation?. Open Journal of Proteomics and Genomics, 2022, 7, 001-005.	0.5	2
549	mRNA vaccine-a desirable therapeutic strategy for surmounting COVID-19 pandemic. Human Vaccines and Immunotherapeutics, 2022, 18, 2040330.	1.4	5
550	Effectiveness and safety of SARSâ€CoVâ€2 vaccine in Inflammatory Bowel Disease patients: a systematic review, metaâ€analysis and metaâ€regression. Alimentary Pharmacology and Therapeutics, 2022, 55, 1244-1264.	1.9	17
551	Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice. Cell, 2022, 185, 1572-1587.e11.	13.5	71
552	Myocarditis and COVID-19 mRNA vaccines: a mechanistic hypothesis involving dsRNA. Future Virology, 2022, 17, 191-196.	0.9	17
553	Antisense technology as a potential strategy for the treatment of coronaviruses infection: With focus on COVIDâ€19. IET Nanobiotechnology, 2022, 16, 67-77.	1.9	4
554	Defining the risk of SARS-CoV-2 variants on immune protection. Nature, 2022, 605, 640-652.	13.7	117
555	Stopping pandemics before they start: Lessons learned from SARS-CoV-2. Science, 2022, 375, 1133-1139.	6.0	58
556	Optimization of SARS-CoV-2 Pseudovirion Production in Lentivirus Backbone With a Novel Liposomal System. Frontiers in Pharmacology, 2022, 13, 840727.	1.6	4
557	Current Status and Future Perspectives on MRNA Drug Manufacturing. Molecular Pharmaceutics, 2022, 19, 1047-1058.	2.3	44
558	Rational Development of a Polysaccharideâ€“Proteinâ€Conjugated Nanoparticle Vaccine Against SARSâ€CoVâ€2 Variants and Streptococcus pneumoniae. Advanced Materials, 2022, 34, e2200443.	11.1	11
559	COVID-19 Vaccines and SARS-CoV-2 Transmission in the Era of New Variants: A Review and Perspective. Open Forum Infectious Diseases, 2022, 9, ofac124.	0.4	25

#	Article	IF	Citations
561	Mapping Data to Deep Understanding: Making the Most of the Deluge of SARS-CoV-2 Genome Sequences. MSystems, 2022, 7, e0003522.	1.7	5
562	Modification of Lipid-Based Nanoparticles: An Efficient Delivery System for Nucleic Acid-Based Immunotherapy. Molecules, 2022, 27, 1943.	1.7	22
563	Coagulopathy and Fibrinolytic Pathophysiology in COVID-19 and SARS-CoV-2 Vaccination. International Journal of Molecular Sciences, 2022, 23, 3338.	1.8	11
564	Immunogenicity mechanism of mRNA vaccines and their limitations in promoting adaptive protection against SARS-CoV-2. PeerJ, 2022, 10, e13083.	0.9	14
565	The Immune Response to SARS-CoV-2: Mechanisms, Aging, Sequelae, and Vaccines. Mini-Reviews in Medicinal Chemistry, 2022, 22, 2166-2185.	1.1	3
566	Current Developments and Challenges of mRNA Vaccines. Annual Review of Biomedical Engineering, 2022, 24, 85-109.	5.7	39
567	Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nature Immunology, 2022, 23, 543-555.	7.0	185
568	Genetic alteration of human MYH6 is mimicked by SARS-CoV-2 polyprotein: mapping viral variants of cardiac interest. Cell Death Discovery, 2022, 8, 124.	2.0	4
570	Detection, prevention and treatment of COVIDâ€19 and opportunities for nanobiotechnology. View, 2022, 3, .	2.7	8
573	Insights From Early Clinical Trials Assessing Response to mRNA SARS-CoV-2 Vaccination in Immunocompromised Patients. Frontiers in Immunology, 2022, 13, 827242.	2.2	5
574	Recent Advances in Delivery Systems for Genetic and Other Novel Vaccines. Advanced Materials, 2022, 34, e2107946.	11.1	10
575	A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection. Science Immunology, 2022, 7, eabo0226.	5.6	22
576	Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics. Nature Communications, 2022, 13, 1536.	5.8	93
577	Architecture and antigenicity of the Nipah virus attachment glycoprotein. Science, 2022, 375, 1373-1378.	6.0	33
578	The Unexpected Importance of the Primary Structure of the Hydrophobic Part of One-Component Ionizable Amphiphilic Janus Dendrimers in Targeted mRNA Delivery Activity. Journal of the American Chemical Society, 2022, 144, 4746-4753.	6.6	43
579	Use of analgesics/antipyretics in the management of symptoms associated with COVID-19 vaccination. Npj Vaccines, 2022, 7, 31.	2.9	21
580	A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time. Pathogens, 2022, 11, 368.	1.2	23
582	Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs. Cell Reports Methods, 2022, 2, 100181.	1.4	9

#	Article	IF	Citations
585	Advances in purification of SARS-CoV-2 spike ectodomain protein using high-throughput screening and non-affinity methods. Scientific Reports, 2022, 12, 4458.	1.6	4
586	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. Journal of Personalized Medicine, 2022, 12, 386.	1.1	5
587	mRNA Vaccines as an Efficient Approach for the Rapid and Robust Induction of Host Immunity Against SARS-CoV-2. SN Comprehensive Clinical Medicine, 2022, 4, 88.	0.3	5
588	Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell, 2022, 185, 1728-1744.e16.	13.5	211
590	Could computer models be the key to better COVID vaccines?. Nature, 2022, 604, 22-25.	13.7	4
591	Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2. Future Microbiology, 2022, 17, 417-424.	1.0	11
592	From Bench Side to Bed-Travelling on a Road to Get a Safe and Effective Vaccine against COVID-19, Day to Save the Life. Recent Patents on Biotechnology, 2022, 16, 2-5.	0.4	4
593	RBD trimer mRNA vaccine elicits broad and protective immune responses against SARS-CoV-2 variants. IScience, 2022, 25, 104043.	1.9	19
594	Whatâ€™s Next after Lipid Nanoparticles? A Perspective on Enablers of Nucleic Acid Therapeutics. Bioconjugate Chemistry, 2022, 33, 1996-2007.	1.8	7
595	The Animal Origin of Major Human Infectious Diseases: What Can Past Epidemics Teach Us About Preventing the Next Pandemic?. Zoonoses, 2022, 2, .	0.5	14
596	Messenger ribonucleic acid vaccines for severe acute respiratory syndrome coronavirus-2 â€“ a review. Translational Research, 2022, 242, 1-19.	2.2	3
597	Th2-Oriented Immune Serum After SARS-CoV-2 Vaccination Does Not Enhance Infection In Vitro. Frontiers in Immunology, 2022, 13, 882856.	2.2	4
598	Delivery of mRNA for regulating functions of immune cells. Journal of Controlled Release, 2022, 345, 494-511.	4.8	28
599	Physical and chemical advances of synthetic delivery vehicles to enhance mRNA vaccine efficacy. Journal of Controlled Release, 2022, 345, 405-416.	4.8	5
600	Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids. Advanced Drug Delivery Reviews, 2022, 184, 114197.	6.6	29
601	mRNA vaccines for COVID-19 and diverse diseases. Journal of Controlled Release, 2022, 345, 314-333.	4.8	50
602	Therapeutic Potential of HNF4Îł in End-stage Liver Disease. Organogenesis, 2021, 17, 126-135.	0.4	2
603	COVID-19 Vaccine Development in Japan: Why Does It Fall Behind?. Trends in the Sciences, 2021, 26, 10_58-10_64.	0.0	0

#	Article	IF	Citations
604	Discordance Between SARS-CoV-2â€“specific Cell-mediated and Antibody Responses Elicited by mRNA-1273 Vaccine in Kidney and Liver Transplant Recipients. Transplantation Direct, 2021, 7, e794.	0.8	28
605	Compassion and Empathy in Basic Medical Science Teaching: A Suggested Model. Cureus, 2021, 13, e20205.	0.2	1
606	Vaccines Targeting Numerous Coronavirus Antigens, Ensuring Broader Global Population Coverage: Multi-epitope and Multi-patch Vaccines. Methods in Molecular Biology, 2022, 2410, 149-175.	0.4	5
607	Spike2Vec: An Efficient and Scalable Embedding Approach for COVID-19 Spike Sequences. , 2021, , .		38
608	mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship. Vaccines, 2021, 9, 1503.	2.1	23
609	Human neutralizing antibodies for SARS-CoV-2 prevention and immunotherapy. Immunotherapy Advances, 2022, 2, .	1.2	9
610	CRISPR Engineering of Bacteriophage T4 to Design Vaccines Against SARS-CoV-2 and Emerging Pathogens. Methods in Molecular Biology, 2022, 2410, 209-228.	0.4	7
614	mRNA Therapeutic Modalities Design, Formulation and Manufacturing under Pharma 4.0 Principles. Biomedicines, 2022, 10, 50.	1.4	30
615	COVID-19 phase 4 vaccine candidates, effectiveness on SARS-CoV-2 variants, neutralizing antibody, rare side effects, traditional and nano-based vaccine platforms: a review. 3 Biotech, 2022, 12, 15.	1.1	20
616	The Development of SARS-CoV-2 Variants: The Gene Makes the Disease. Journal of Developmental Biology, 2021, 9, 58.	0.9	27
617	The Development of mRNA Vaccines for Infectious Diseases: Recent Updates. Infection and Drug Resistance, 2021, Volume 14, 5271-5285.	1.1	16
618	Improvement of mRNA Delivery Efficiency to a T Cell Line by Modulating PEG-Lipid Content and Phospholipid Components of Lipid Nanoparticles. Pharmaceutics, 2021, 13, 2097.	2.0	11
620	Advances in the design and development of SARS-CoV-2 vaccines. Military Medical Research, 2021, 8, 67.	1.9	26
622	State-of-the-art preclinical evaluation of COVID-19 vaccine candidates. Exploration of Immunology, 0, , 440-460.	1.7	0
623	A Promising Vaccination Strategy against COVID-19 on the Horizon: Heterologous Immunization. Journal of Microbiology and Biotechnology, 2021, 31, 1601-1614.	0.9	8
624	Modified mRNA-Based Vaccines Against Coronavirus Disease 2019. Cell Transplantation, 2022, 31, 096368972210902.	1.2	3
625	Nearest neighbor rules for RNA helix folding thermodynamics: improved end effects. Nucleic Acids Research, 2022, 50, 5251-5262.	6.5	12
626	COVID-19 mRNA Vaccines Preserve Immunogenicity after Re-Freezing. Vaccines, 2022, 10, 594.	2.1	4

#	Article	IF	Citations
627	Nano toolbox in immune modulation and nanovaccines. Trends in Biotechnology, 2022, 40, 1195-1212.	4.9	31
628	TRMT6/61A-dependent base methylation of tRNA-derived fragments regulates gene-silencing activity and the unfolded protein response in bladder cancer. Nature Communications, 2022, 13, 2165.	5.8	43
629	Anti-coronavirus vaccines will not accelerate the transition of humanity to a non-pandemic period, but the pandemic will take fewer victims. Inflammation Research, 2022, , 1.	1.6	0
630	mRNA vaccines: the most recent clinical applications of synthetic mRNA. Archives of Pharmacal Research, 2022, 45, 245-262.	2.7	27
631	Decoding pseudouridine: an emerging target for therapeutic development. Trends in Pharmacological Sciences, 2022, 43, 522-535.	4.0	32
632	Long-Term, CD4+ Memory T Cell Response to SARS-CoV-2. Frontiers in Immunology, 2022, 13, 800070.	2.2	12
633	mRNA Vaccines: Why Is the Biology of Retroposition Ignored?. Genes, 2022, 13, 719.	1.0	16
634	Isotope Labels Combined with Solution NMR Spectroscopy Make Visible the Invisible Conformations of Small-to-Large RNAs. Chemical Reviews, 2022, 122, 9357-9394.	23.0	12
635	Nucleic Acids as Biotools at the Interface between Chemistry and Nanomedicine in the COVID-19 Era. International Journal of Molecular Sciences, 2022, 23, 4359.	1.8	6
636	Preclinical study of a DNA vaccine targeting SARS-CoV-2. Current Research in Translational Medicine, 2022, 70, 103348.	1.2	9
638	Covax-19/SpikogenÂ® vaccine based on recombinant spike protein extracellular domain with Advax-CpG55.2 adjuvant provides single dose protection against SARS-CoV-2 infection in hamsters. Vaccine, 2022, 40, 3182-3192.	1.7	25
639	Advances in COVID-19 mRNA vaccine development. Signal Transduction and Targeted Therapy, 2022, 7, 94.	7.1	177
640	Wonder of wonders, miracle of miracles: the unprecedented speed of COVID-19 science. Physiological Reviews, 2022, 102, 1569-1577.	13.1	9
641	Current strategies and future perspectives in COVID-19 therapy. , 2022, , 169-227.		0
642	Vaccine strategy against COVID-19 with a focus on the Omicron and stealth Omicron variants: Life Cycle Committee Recommendations. , 0, 2, .		11
643	Variant-specific vaccination induces systems immune responses and potent inÂvivo protection against SARS-CoV-2. Cell Reports Medicine, 2022, 3, 100634.	3.3	10
644	Low-Dose SARS-CoV-2 S-Trimer with an Emulsion Adjuvant Induced Th1-Biased Protective Immunity. International Journal of Molecular Sciences, 2022, 23, 4902.	1.8	9
646	Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications. Nano Convergence, 2022, 9, 19.	6.3	12

#	Article	IF	Citations
647	Quality by Design for enabling RNA platform production processes. Trends in Biotechnology, 2022, 40, 1213-1228.	4.9	36
648	Universal Flu mRNA Vaccine: Promises, Prospects, and Problems. Vaccines, 2022, 10, 709.	2.1	7
650	An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa. Molecular Therapy, 2022, 30, 2984-2997.	3.7	17
651	Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects. Frontiers in Immunology, 2022, 13, 843928.	2.2	25
652	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. Cell Reports, 2022, 39, 110812.	2.9	287
653	Course of Fecal Calprotectin after mRNA SARS-CoV-2 Vaccination in Patients with Inflammatory Bowel Diseases. Vaccines, 2022, 10, 759.	2.1	1
654	A Precision Adjuvant Approach to Enhance Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines Optimized for Immunologically Distinct Vulnerable Populations. Clinical Infectious Diseases, 2022, 75, S30-S36.	2.9	7
655	Safety, efficacy, and immunogenicity of COVID-19 vaccines; a systematic review. Immunological Medicine, 2022, 45, 225-237.	1.4	18
656	Thromboembolism after COVID-19 Vaccination: A Systematic Review of Such Events in 286 Patients. Annals of Vascular Surgery, 2022, 84, 12-20.e1.	0.4	17
657	Characterization and Sequence Mapping of Large RNA and mRNA Therapeutics Using Mass Spectrometry. Analytical Chemistry, 2022, 94, 7339-7349.	3.2	22
658	The potential of RNA-based therapy for kidney diseases. Pediatric Nephrology, 2023, 38, 327-344.	0.9	14
659	Poloxamer-188 Adjuvant Efficiently Maintains Adaptive Immunity of SARS-CoV-2 RBD Subunit Vaccination through Repressing p38MAPK Signaling. Vaccines, 2022, 10, 715.	2.1	1
660	The clinical progress of mRNA vaccines and immunotherapies. Nature Biotechnology, 2022, 40, 840-854.	9.4	248
661	A Review of Different Vaccines and Strategies to Combat COVID-19. Vaccines, 2022, 10, 737.	2.1	8
662	SARS-CoV-2: overview of immune response, insights into vaccine platforms and their challenges. Exploration of Immunology, 0, , 245-263.	1.7	0
663	Adjuvanting a subunit SARS-CoV-2 vaccine with clinically relevant adjuvants induces durable protection in mice. Npj Vaccines, 2022, 7, .	2.9	32
664	Development of an LNP-Encapsulated mRNA-RBD Vaccine against SARS-CoV-2 and Its Variants. Pharmaceutics, 2022, 14, 1101.	2.0	15
665	Structure, receptor recognition, and antigenicity of the human coronavirus CCoV-HuPn-2018 spike glycoprotein. Cell, 2022, 185, 2279-2291.e17.	13.5	25

#	Article	IF	Citations
666	mRNA-based therapeutics: powerful and versatile tools to combat diseases. Signal Transduction and Targeted Therapy, 2022, 7, .	7.1	160
669	Facemask wearing does not impact neuro-electrical brain activity. Scientific Reports, 2022, 12, .	1.6	4
671	A single immunization with cellular vaccine confers dual protection against <scp>SARSâ€CoV</scp>â€2 and cancer. Cancer Science, 2022, 113, 2536-2547.	1.7	6
673	Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination. Frontiers in Immunology, 0, 13, .	2.2	4
674	Development and Evaluation about â€œ2nd-waveâ€•COVID-19 Vaccines. Yakugaku Zasshi, 2022, 142, 619-627.	0.0	1
675	Chimeric Antigen by the Fusion of SARS-CoV-2 Receptor Binding Domain with the Extracellular Domain of Human CD154: A Promising Improved Vaccine Candidate. Vaccines, 2022, 10, 897.	2.1	5
676	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	2.0	1
677	A DNA vaccine candidate delivered by an electroacupuncture machine provides protective immunity against SARS-CoV-2 infection. Npj Vaccines, 2022, 7, .	2.9	21
678	mRNA-1273 vaccination protects against SARS-CoV-2â€“elicited lung inflammation in nonhuman primates. JCI Insight, 2022, 7, .	2.3	3
679	Severe Acute Respiratory Syndrome Corona Virus-2 (SARS-CoV-2) Serology in the Vaccination Era and Post Booster Vaccination. SSRN Electronic Journal, 0, , .	0.4	0
680	Advances in Circular RNA and Its Applications. International Journal of Medical Sciences, 2022, 19, 975-985.	1.1	46
681	Inhalable exosomes outperform liposomes as mRNA and protein drug carriers to the lung. , 2022, 1, 100002.		34
683	Codelivery of SARS-CoV-2 Prefusion-Spike Protein with CBLB502 by a Dual-Chambered Ferritin Nanocarrier Potentiates Systemic and Mucosal Immunity. ACS Applied Bio Materials, 2022, 5, 3329-3337.	2.3	1
684	Lessons from Acquired Natural Immunity and Clinical Trials to Inform Next-Generation Human Cytomegalovirus Vaccine Development. Annual Review of Virology, 2022, 9, 491-520.	3.0	13
685	Addressing COVID-19 vaccine hesitancy. Drugs in Context, 0, 11, 1-19.	1.0	11
686	Immune Response to SARS-CoV-2 Vaccines. Biomedicines, 2022, 10, 1464.	1.4	24
687	Omicron-specific mRNA vaccination alone and as a heterologous booster against SARS-CoV-2. Nature Communications, 2022, 13, .	5.8	40
688	Lipid Nanoparticle Technologies for Nucleic Acid Delivery: A Nanoarchitectonics Perspective. Advanced Functional Materials, 2022, 32, .	7.8	36

#	Article	IF	Citations
689	Vaccine Preventable Zoonotic Diseases: Challenges and Opportunities for Public Health Progress. Vaccines, 2022, 10, 993.	2.1	10
691	Potency of Fusion-Inhibitory Lipopeptides against SARS-CoV-2 Variants of Concern. MBio, 2022, 13, .	1.8	9
693	At the nexus of science, engineering, and medicine: Pasteur's quadrant reconsidered. , 2022, 1, .		0
694	Advances in nanotechnology application in biosafety materials: A crucial response to COVID-19 pandemic. Biosafety and Health, 2022, 4, 347-363.	1.2	2
695	A Brighton Collaboration standardized template with key considerations for a benefit/risk assessment for the Moderna COVID-19 Vaccine (mRNA-1273). Vaccine, 2022, 40, 5275-5293.	1.7	3
696	Peptide Triazole Inhibitors of HIV-1: Hijackers of Env Metastability. Current Protein and Peptide Science, 2023, 24, 59-77.	0.7	4
697	A one-year follow-up study on dynamic changes of leukocyte subsets and virus-specific antibodies of patients with COVID-19 in Sichuan, China. International Journal of Medical Sciences, 2022, 19, 1122-1130.	1.1	0
698	Nanovaccines against viral infections: Current trends and future prospects. , 2022, , 315-328.		1
699	Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	38
700	Intranasal immunization with avian paramyxovirus type 3 expressing SARS-CoV-2 spike protein protects hamsters against SARS-CoV-2. Npj Vaccines, 2022, 7, .	2.9	7
701	Immune Persistence and Safety After SARS-CoV-2 BNT162b1 mRNA Vaccination in Chinese Adults: A Randomized, Placebo-Controlled, Double-Blind Phase 1 Trial. Advances in Therapy, 2022, 39, 3789-3798.	1.3	3
702	Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant. Frontiers in Immunology, 0, 13, .	2.2	6
703	COVID-19 Variant Detection with a High-Fidelity CRISPR-Cas12 Enzyme. Journal of Clinical Microbiology, 2022, 60, .	1.8	18
704	Immune Response in Regard to Hypersensitivity Reactions after COVID-19 Vaccination. Biomedicines, 2022, 10, 1641.	1.4	3
705	Will Peptides Help to Stop COVID-19?. Biochemistry (Moscow), 2022, 87, 590-604.	0.7	1
706	Protein-protein conjugation enhances the immunogenicity of SARS-CoV-2 receptor-binding domain (RBD) vaccines. IScience, 2022, 25, 104739.	1.9	4
707	Vaccine-elicited murine antibody WS6 neutralizes diverse beta-coronaviruses by recognizing a helical stem supersite of vulnerability. Structure, 2022, 30, 1233-1244.e7.	1.6	13
708	Multiplexed LNP-mRNA vaccination against pathogenic coronavirus species. Cell Reports, 2022, 40, 111160.	2.9	9

#	Article	IF	Citations
709	SARS-CoV-2 Vaccines: The Mucosal Immunity Imperative. Mayo Clinic Proceedings, 2022, 97, 1771-1773.	1.4	6
710	Delivering an mRNA vaccine using a lymphatic drug delivery device improves humoral and cellular immunity against SARS-CoV-2. Journal of Molecular Cell Biology, 2022, 14, .	1.5	2
711	Neutralizing antibody responses against <scp>SARSâ€CoV</scp>â€2 in patients with plasma cell disorders who are on active treatment after two doses of <scp>mRNA</scp> vaccination. European Journal of Haematology, 2022, 109, 458-464.	1.1	9
712	Respiratory Syncytial Virus Disease in Young Children and Older Adults in Europe: A Burden and Economic Perspective. Journal of Infectious Diseases, 0, , .	1.9	8
713	Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination Against Infectious Diseases. Frontiers in Immunology, 0, 13, .	2.2	7
714	From a recombinant key antigen to an accurate, affordable serological test: Lessons learnt from COVID-19 for future pandemics. Biochemical Engineering Journal, 2022, 186, 108537.	1.8	22
715	Preclinical Immunogenicity and Efficacy of a Multiple Antigen-Presenting System (MAPSTM) SARS-CoV-2 Vaccine. Vaccines, 2022, 10, 1069.	2.1	2
716	Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. Frontiers in Immunology, 0, 13, .	2.2	8
717	Inhalable dry powder mRNA vaccines based on extracellular vesicles. Matter, 2022, 5, 2960-2974.	5.0	75
718	Relatively rapid evolution rates of SARS-CoV-2 spike gene at the primary stage of massive vaccination. Biosafety and Health, 2022, 4, 228-233.	1.2	6
719	The Pivotal Role of Chemical Modifications in mRNA Therapeutics. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	15
720	SARS-CoV-2 infection produces chronic pulmonary epithelial and immune cell dysfunction with fibrosis in mice. Science Translational Medicine, 2022, 14, .	5.8	55
721	Lipid nanoparticles in the development of mRNA vaccines for COVID-19. Journal of Drug Delivery Science and Technology, 2022, 74, 103553.	1.4	44
722	Lipid-peptide nanocomplexes for mRNA delivery in vitro and in vivo. Journal of Controlled Release, 2022, 348, 786-797.	4.8	16
723	A circular mRNA vaccine prototype producing VFLIP-X spike confers a broad neutralization of SARS-CoV-2 variants by mouse sera. Antiviral Research, 2022, 204, 105370.	1.9	16
724	Coronaviruses. , 2023, , 277-306.		0
725	Lipidâ€Polymer Hybrid â€œParticleâ€inâ€Particleâ€•Nanostructure Gene Delivery Platform Explored for Lyophilizable DNA and mRNA COVIDâ€19 Vaccines. Advanced Functional Materials, 2022, 32, .	7.8	16
726	RNA-based therapeutics: an overview and prospectus. Cell Death and Disease, 2022, 13, .	2.7	137

#	Article	IF	Citations
727	Single-shot AAV-vectored vaccine against SARS-CoV-2 with fast and long-lasting immunity. Acta Pharmaceutica Sinica B, 2023, 13, 2219-2233.	5.7	9
728	mRNA Vaccines Against SARSâ€CoVâ€2 Variants Delivered by Lipid Nanoparticles Based on Novel Ionizable Lipids. Advanced Functional Materials, 2022, 32, .	7.8	31
729	mRNA-based modalities for infectious disease management. Nano Research, 2023, 16, 672-691.	5.8	7
730	â€œDonâ€™t Look Upâ€•Your Scienceâ€”Herd Immunity or Herd Mentality?. Microorganisms, 2022, 10, 1463.	1.6	2
731	Nanotechnologyâ€facilitated vaccine development during the coronavirus disease 2019 (COVIDâ€19) pandemic. Exploration, 2022, 2, .	5.4	22
732	Emerging Roles of Circ-ZNF609 in Multiple Human Diseases. Frontiers in Genetics, 0, 13, .	1.1	4
733	Pathological and protective roles of dendritic cells in Mycobacterium tuberculosis infection: Interaction between host immune responses and pathogen evasion. Frontiers in Cellular and Infection Microbiology, 0, 12, .	1.8	9
734	Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines. Science, 2022, 377, 890-894.	6.0	142
735	Rational development of a combined mRNA vaccine against COVID-19 and influenza. Npj Vaccines, 2022, 7, .	2.9	16
737	Prototype Pathogen Approach for Vaccine and Monoclonal Antibody Development: A Critical Component of the NIAID Plan for Pandemic Preparedness. Journal of Infectious Diseases, 2023, 227, 1433-1441.	1.9	12
738	Tools shaping drug discovery and development. Biophysics Reviews, 2022, 3, .	1.0	3
739	Understanding the cellular pathogenesis of COVID-19 symptoms using organoid technology. Organoid, 0, 2, e16.	0.0	0
740	A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine. MBio, 2022, 13, .	1.8	17
741	Mucosal administration of a live attenuated recombinant COVID-19 vaccine protects nonhuman primates from SARS-CoV-2. Npj Vaccines, 2022, 7, .	2.9	23
742	N1-methyl-pseudouridine is incorporated with higher fidelity than pseudouridine in synthetic RNAs. Scientific Reports, 2022, 12, .	1.6	13
744	Think like a Virus: Toward Improving Nanovaccine Development against SARS-CoV-2. Viruses, 2022, 14, 1553.	1.5	9
745	Ascendancy of semi-synthetic biomaterials from design towards democratization. Nature Materials, 2022, 21, 989-992.	13.3	7
746	Self-amplifying mRNA vaccines: Mode of action, design, development and optimization. Drug Discovery Today, 2022, 27, 103341.	3.2	7

#	Article	IF	Citations
747	mRNA vaccines in the prevention and treatment of diseases. MedComm, 2022, 3, .	3.1	14
748	Nanoparticles in clinical trials of COVID-19: An update. International Journal of Surgery, 2022, 104, 106818.	1.1	22
749	<scp>SARSâ€CoV</scp> â€2 spike trimer vaccine expressed in Nicotiana benthamiana adjuvanted with Alum elicits protective immune responses in mice. Plant Biotechnology Journal, 0, , .	4.1	3
750	Humoral responses to the SARS-CoV-2 spike and receptor binding domain in context of pre-existing immunity confer broad sarbecovirus neutralization. Frontiers in Immunology, 0, 13, .	2.2	2
751	Three-month follow-up of durability of response to the third dose of the SARS-CoV-2 BNT162b2 vaccine in adults aged 60 years and older: a prospective cohort study. BMJ Open, 2022, 12, e061584.	0.8	4
752	SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors. Environmental Science and Pollution Research, 2022, 29, 69117-69136.	2.7	7
754	Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses. Immunity, 2022, 55, 1680-1692.e8.	6.6	21
755	Lipid nanoparticle-based mRNA vaccines in cancers: Current advances and future prospects. Frontiers in Immunology, 0, 13, .	2.2	19
756	Vaccine-associated enhanced respiratory pathology in COVID-19 hamsters after TH2-biased immunization. Cell Reports, 2022, 40, 111214.	2.9	24
757	Effective gene therapy of Stargardt disease with PEG-ECO/pGRK1-ABCA4-S/MAR nanoparticles. Molecular Therapy - Nucleic Acids, 2022, 29, 823-835.	2.3	13
759	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. Nature Communications, 2022, 13, .	5.8	23
760	Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape. Lancet Infectious Diseases, The, 2023, 23, e2-e21.	4.6	138
761	Harnessing nucleic acid technologies for human health on earth and in space. Life Sciences in Space Research, 2022, 35, 113-126.	1.2	2
762	Targeted therapy in Coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. International Immunopharmacology, 2022, 111, 109161.	1.7	9
763	Regulation of innate and adaptive immunity using herbal medicine: benefits for the COVID-19 vaccination. , 2022, 2, 196-206.		6
764	SARS-CoV-2 mRNA-vaccine candidate; COReNAPCINÂ®, induces robust humoral and cellular immunity in mice and non-human primates. Npj Vaccines, 2022, 7, .	2.9	5
765	mRNA produced by VSW-3 RNAP has high-level translation efficiency with low inflammatory stimulation. , 2022, 1, 100056.		9
766	COVID-19: Vaccines and therapeutics. Bioorganic and Medicinal Chemistry Letters, 2022, 75, 128987.	1.0	4

#	Article	IF	Citations
767	Polyethylene glycol (PEG): The nature, immunogenicity, and role in the hypersensitivity of PEGylated products. Journal of Controlled Release, 2022, 351, 215-230.	4.8	78
768	Intracellular delivery of messenger RNA to macrophages with surfactant-derived lipid nanoparticles. Materials Today Advances, 2022, 16, 100295.	2.5	3
769	Preparation of Messenger RNA-Loaded Nanomedicine Applied on Tissue Engineering and Regenerative Medicine. RNA Technologies, 2022, , 397-428.	0.2	0
770	Nature of viruses and pandemics: Coronaviruses. Current Research in Immunology, 2022, 3, 151-158.	1.2	3
771	Clinical Development of mRNA Vaccines: Challenges and Opportunities. Current Topics in Microbiology and Immunology, 2022, , 167-186.	0.7	2
772	Cationic polymer synergizing with a disulfide-containing enhancer achieved efficient nucleic acid and protein delivery. Biomaterials Science, 2022, 10, 6230-6243.	2.6	9
773	Covid-19: Treatment conclusion with kinds of vaccine and drugs. AIP Conference Proceedings, 2022, , .	0.3	0
774	Vaccine History: From Smallpox to Covid-19. Engineering Materials, 2022, , 519-543.	0.3	0
775	COVID-19 Infection and Response to Vaccination in Chronic Kidney Disease and Renal Transplantation: A Brief Presentation. Life, 2022, 12, 1358.	1.1	2
776	SARS-CoV-2 and extracellular vesicles: An intricate interplay in pathogenesis, diagnosis and treatment. Frontiers in Nanotechnology, 0, 4, .	2.4	3
777	Status and Challenges for Vaccination against Avian H9N2 Influenza Virus in China. Life, 2022, 12, 1326.	1.1	11
778	Mapping monoclonal anti-SARS-CoV-2 antibody repertoires against diverse coronavirus antigens. Frontiers in Immunology, 0, 13, .	2.2	2
779	Covalent Catalytic Strategies for Enzymes That Modify RNA Molecules on their Tripartite Building Blocks. ACS Chemical Biology, 2022, 17, 2686-2703.	1.6	3
780	RNA therapeutics: updates and future potential. Science China Life Sciences, 2023, 66, 12-30.	2.3	31
781	Design and lyophilization of lipid nanoparticles for mRNA vaccine and its robust immune response in mice and nonhuman primates. Molecular Therapy - Nucleic Acids, 2022, 30, 226-240.	2.3	19
782	Potential mouse models of coronavirus-related immune injury. Frontiers in Immunology, 0, 13, .	2.2	1
784	Leveraging Biological Buffers for Efficient Messenger RNA Delivery via Lipid Nanoparticles. Molecular Pharmaceutics, 2022, 19, 4275-4285.	2.3	10
785	Bioinformatics-based SARS-CoV-2 epitopes design and the impact of Spike protein mutants on epitope humoral immunities. Immunobiology, 2022, , 152287.	0.8	2

#	Article	IF	Citations
788	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. Science Translational Medicine, 2022, 14, .	5.8	55
789	Immune responses to SARS-CoV-2 infection and COVID-19 vaccines. Exploration of Immunology, 2022, 2, 648-664.	1.7	1
790	Design of the SARS-CoV-2 RBD vaccine antigen improves neutralizing antibody response. Science Advances, 2022, 8, .	4.7	22
791	Molecular characterization and sequecing analysis of SARS-CoV-2 genome in Minas Gerais, Brazil. Biologicals, 2022, 80, 43-52.	0.5	0
792	Potent monoclonal antibodies neutralize Omicron sublineages and other SARS-CoV-2 variants. Cell Reports, 2022, 41, 111528.	2.9	6
794	Long-Term Antibody Response to SARS-CoV-2 in Children. Journal of Clinical Immunology, 2023, 43, 46-56.	2.0	8
796	Disinfection effect of hexadecyl pyridinium chloride on SARS-CoV-2 in vitro. Intervirology, 0, , .	1.2	0
797	Design principles of bioinspired interfaces for biomedical applications in therapeutics and imaging. Frontiers in Chemistry, 0, 10, .	1.8	2
798	A critical overview of current progress for COVID-19: development of vaccines, antiviralÂdrugs, and therapeutic antibodies. Journal of Biomedical Science, 2022, 29, .	2.6	64
799	COVID-19 and cellular senescence. Nature Reviews Immunology, 2023, 23, 251-263.	10.6	54
800	Development of variantâ€proof severe acute respiratory syndrome coronavirus 2, panâ€sarbecovirus, and panâ€î²â€coronavirus vaccines. Journal of Medical Virology, 2023, 95, .	2.5	12
801	Lessons from the pandemic: Responding to emerging zoonotic viral diseasesâ€"a Keystone Symposia report. Annals of the New York Academy of Sciences, 2022, 1518, 209-225.	1.8	4
802	mRNA vaccines: A novel weapon to control infectious diseases. Frontiers in Microbiology, 0, 13, .	1.5	10
804	A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. EBioMedicine, 2022, 85, 104297.	2.7	11
805	Engagement of scientists with the public and policymakers to promote alternative methods. ALTEX: Alternatives To Animal Experimentation, 2022, , 543-559.	0.9	2
806	Design and Self-Assembly of Therapeutic Nucleic Acid Nanoparticles (NANPs) with Controlled Immunological Properties. , 2022, , 1-29.		0
807	Lipid nanoparticles for mRNA delivery. Drug Delivery System, 2022, 37, 237-246.	0.0	1
808	Virus-like Particles (VLPs) as Important Tools for Flavivirus Vaccine Development. Biologics, 2022, 2, 226-242.	2.3	2

#	Article	IF	Citations
809	Cell Entry and Unusual Replication of SARS-CoV-2. Current Drug Targets, 2022, 23, 1539-1554.	1.0	1
810	Translation suppression underlies the restrained COVID-19 mRNA vaccine response in the high-risk immunocompromised group. Frontiers in Immunology, 0, 13, .	2.2	0
811	Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications. Journal of Pharmaceutical Analysis, 2023, 13, 1-10.	2.4	1
812	Self-Amplifying RNA Approach for Protein Replacement Therapy. International Journal of Molecular Sciences, 2022, 23, 12884.	1.8	13
813	Development of SARSâ€CoVâ€2 animal vaccines using a stable and efficient NDV expression system. Journal of Medical Virology, 2023, 95, .	2.5	2
814	Booster dose of mRNA vaccine augments waning T cell and antibody responses against SARS-CoV-2. Frontiers in Immunology, 0, 13, .	2.2	16
815	Immunisation Using Novel DNA Vaccine Encoding Virus Membrane Fusion Complex and Chemokine Genes Shows High Protection from HSV-2. Viruses, 2022, 14, 2317.	1.5	0
816	SARS-CoV-2 tetrameric RBD protein blocks viral infection and induces potent neutralizing antibody response. Frontiers in Immunology, 0, 13, .	2.2	2
817	Broad Based Immunity?. Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, 2022, 41, 229-230.	0.8	0
818	Zebrafish as a platform to evaluate the potential of lipidic nanoemulsions for gene therapy in cancer. Frontiers in Pharmacology, 0, 13, .	1.6	1
819	Development of Bivalent mRNA Vaccines against SARS-CoV-2 Variants. Vaccines, 2022, 10, 1807.	2.1	9
820	Enzyme-Catalyzed One-Step Synthesis of Ionizable Cationic Lipids for Lipid Nanoparticle-Based mRNA COVID-19 Vaccines. ACS Nano, 2022, 16, 18936-18950.	7.3	22
821	Nucleic Acid Vaccines against SARS-CoV-2. Vaccines, 2022, 10, 1849.	2.1	10
822	An overview of structural approaches to study therapeutic RNAs. Frontiers in Molecular Biosciences, 0, 9, .	1.6	0
824	Modified Nucleotides for Chemical and Enzymatic Synthesis of Therapeutic RNA. Current Medicinal Chemistry, 2023, 30, 1320-1347.	1.2	3
826	Immunization with a Prefusion SARS-CoV-2 Spike Protein Vaccine (RBMRNA-176) Protects against Viral Challenge in Mice and Nonhuman Primates. Vaccines, 2022, 10, 1698.	2.1	4
827	RNA Editing Therapeutics: Advances, Challenges and Perspectives on Combating Heart Disease. Cardiovascular Drugs and Therapy, 2023, 37, 401-411.	1.3	6
828	The Burden of Omicron Variant in Pakistan: An Updated Review. Covid, 2022, 2, 1460-1476.	0.7	1

#	Article	IF	Citations
829	Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice. Nature Medicine, 2023, 29, 247-257.	15.2	98
830	Rapid Generation of Circulating and Mucosal Decoy Human ACE2 using mRNA Nanotherapeutics for the Potential Treatment of SARSâ€CoVâ€2. Advanced Science, 2022, 9, .	5.6	17
832	Leishmaniasis Vaccines: Applications of RNA Technology and Targeted Clinical Trial Designs. Pathogens, 2022, 11, 1259.	1.2	4
833	Advancing mRNA technologies for therapies and vaccines: An African context. Frontiers in Immunology, 0, 13, .	2.2	3
834	A self-amplifying RNA vaccine against COVID-19 with long-term room-temperature stability. Npj Vaccines, 2022, 7, .	2.9	24
836	A systematic and thematic analysis of the top 100 cited articles on mRNA vaccine indexed in Scopus database. Human Vaccines and Immunotherapeutics, 0, , .	1.4	2
837	SARS-CoV-2 Omicron (BA.1 and BA.2) specific novel CD8+ and CD4+ T cell epitopes targeting spike protein. ImmunoInformatics, 2022, 8, 100020.	1.2	2
838	Notfallimpfstoffe: Wie sieht die Zukunft aus?. , 2022, , 68-71.		0
839	mRNA vaccines for COVID-19. , 2023, , 611-624.		0
840	Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine is protective in monkeys. Cell, 2022, 185, 4811-4825.e17.	13.5	19
841	SARS-CoV-2 spike conformation determines plasma neutralizing activity elicited by a wide panel of human vaccines. Science Immunology, 2022, 7, .	5.6	42
842	Review of Developments in Combating COVID-19 by Vaccines, Inhibitors, Radiations, and Nonthermal Plasma. Current Issues in Molecular Biology, 2022, 44, 5666-5690.	1.0	4
844	Vaccines on demand, part II: future reality. Expert Opinion on Drug Discovery, 2023, 18, 119-127.	2.5	3
845	Current strategies and perspectives for active and passive immunization against Respiratory Syncytial Virus in childhood. Jornal De Pediatria, 2023, 99, S4-S11.	0.9	10
846	Altering the mRNA-1273 dosing interval impacts the kinetics, quality, and magnitude of immune responses in mice. Frontiers in Immunology, 0, 13, .	2.2	3
847	Intranasal Sendai virusâ€based SARSâ€CoVâ€2 vaccine using a mouse model. Genes To Cells, 0, , .	0.5	1
848	SV-AUC as a stability-indicating method for the characterization of mRNA-LNPs. European Journal of Pharmaceutics and Biopharmaceutics, 2023, 182, 152-156.	2.0	10
849	TEMPO: A transformer-based mutation prediction framework for SARS-CoV-2 evolution. Computers in Biology and Medicine, 2023, 152, 106264.	3.9	4

#	Article	IF	Citations
850	Severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) serology in the vaccination era and post booster vaccination. Journal of Clinical Virology Plus, 2023, 3, 100130.	0.4	0
851	COVID-19 signalome: Potential therapeutic interventions. Cellular Signalling, 2023, 103, 110559.	1.7	5
852	Ethnological aspects of COVID-19. Brazilian Journal of Pharmaceutical Sciences, 0, 58, .	1.2	0
853	Immunogenicity and Efficacy of Monovalent and Bivalent Formulations of a Virus-Like Particle Vaccine against SARS-CoV-2. Vaccines, 2022, 10, 1997.	2.1	4
855	Forty years of investment in HIV research: progress towards ending the HIV pandemic and preparation for future pandemics. Journal of the International AIDS Society, 2022, 25, .	1.2	3
856	Developing New Tools to Fight Human Pathogens: A Journey through the Advances in RNA Technologies. Microorganisms, 2022, 10, 2303.	1.6	1
858	Current state of, prospects for, and obstacles to mRNA vaccine development. Drug Discovery Today, 2023, 28, 103458.	3.2	5
859	Nanomaterials to combat SARS-CoV-2: Strategies to prevent, diagnose and treat COVID-19. Frontiers in Bioengineering and Biotechnology, 0, 10, .	2.0	3
860	Development of a novel circular mRNA vaccine of six protein combinations against Staphylococcus aureus. Journal of Biomolecular Structure and Dynamics, 2023, 41, 10525-10545.	2.0	4
861	Urgency and necessity of Epstein-Barr virus prophylactic vaccines. Npj Vaccines, 2022, 7, .	2.9	20
862	Effectiveness of mRNA, protein subunit vaccine and viral vectors vaccines against SARS-CoV-2 in people over 18 years old: a systematic review. Expert Review of Vaccines, 2023, 22, 35-53.	2.0	8
864	Therapeutic challenges in COVID-19. Current Molecular Medicine, 2022, 23, .	0.6	0
865	Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults. Vaccine, 2023, 41, 1834-1847.	1.7	0
866	A Thermal and Enzymatic Dualâ€Stimuli Responsive DNAâ€Based Nanomachine for Controlled mRNA Delivery. Advanced Science, 2023, 10, .	5.6	8
867	Protease-Independent Production of Poliovirus Virus-like Particles in Pichia pastoris: Implications for Efficient Vaccine Development and Insights into Capsid Assembly. Microbiology Spectrum, 2023, 11, .	1.2	2
868	Clinical trials for accelerating pandemic vaccines. Oxford Review of Economic Policy, 2022, 38, 797-817.	1.0	4
869	Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA. MBio, 2023, 14, .	1.8	5
870	mRNA in the Context of Protein Replacement Therapy. Pharmaceutics, 2023, 15, 166.	2.0	22

#	Article	IF	Citations
871	Acidification-Induced Structure Evolution of Lipid Nanoparticles Correlates with Their In Vitro Gene Transfections. ACS Nano, 2023, 17, 979-990.	7.3	15
872	Integrated mRNA sequence optimization using deep learning. Briefings in Bioinformatics, 2023, 24, .	3.2	5
873	Efficacy of Vaccine Protection Against COVID-19 Virus Infection in Patients with Chronic Liver Diseases. Journal of Clinical and Translational Hepatology, 2023, 000, 000-000.	0.7	0
874	Race with virus evolution: The development and application of mRNA vaccines against SARS-CoV-2. Biomedical Journal, 2023, 46, 70-80.	1.4	8
875	Updated Insights into the T Cell-Mediated Immune Response against SARS-CoV-2: A Step towards Efficient and Reliable Vaccines. Vaccines, 2023, 11, 101.	2.1	14
876	Prevention and Treatment Strategies for Respiratory Syncytial Virus (RSV). Pathogens, 2023, 12, 154.	1.2	14
878	VDDB: A comprehensive resource and machine learning tool for antiviral drug discovery. , 2023, 2, .		0
879	Synergistic Immunity and Protection in Mice by Co-Immunization with DNA Vaccines Encoding the Spike Protein and Other Structural Proteins of SARS-CoV-2. Vaccines, 2023, 11, 243.	2.1	4
880	A hepatitis B virus core antigenâ€based virusâ€like particle vaccine expressing SARSâ€CoVâ€2 B and T cell epitopes induces epitopeâ€specific humoral and cellâ€mediated immune responses but confers limited protection against SARSâ€CoVâ€2 infection. Journal of Medical Virology, 2023, 95, .	2.5	2
881	Neutralizing Efficacy of Encapsulin Nanoparticles against SARS-CoV2 Variants of Concern. Viruses, 2023, 15, 346.	1.5	4
882	mRNAâ€”From COVID-19 Treatment to Cancer Immunotherapy. Biomedicines, 2023, 11, 308.	1.4	3
883	Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications. Frontiers in Immunology, 0, 14, .	2.2	14
884	Iterative Design of Ionizable Lipids for Intramuscular mRNA Delivery. Journal of the American Chemical Society, 2023, 145, 2294-2304.	6.6	24
885	Omics approaches in COVID-19: An overview. , 2023, , 3-21.		0
886	Unsaturated, Trialkyl Ionizable Lipids are Versatile Lipidâ€Nanoparticle Components for Therapeutic and Vaccine Applications. Advanced Materials, 0, , 2209624.	11.1	17
887	Applications of genetic engineering in COVID-19. , 2023, , 219-237.		0
888	Nanomaterials for <scp>mRNA</scp>â€based therapeutics: Challenges and opportunities. Bioengineering and Translational Medicine, 2023, 8, .	3.9	14
889	Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine Trials. JAMA Network Open, 2023, 6, e2251974.	2.8	12

#	Article	IF	Citations
890	A Short Introduction to Vaccines. , 2023, , 1-32.		0
892	SARS-CoV-2 Spike Protein Downregulates Cell Surface Î±7nAChR through a Helical Motif in the Spike Neck. ACS Chemical Neuroscience, 2023, 14, 689-698.	1.7	3
894	Different configurations of SARS-CoV-2 spike protein delivered by integrase-defective lentiviral vectors induce persistent functional immune responses, characterized by distinct immunogenicity profiles. Frontiers in Immunology, 0, 14, .	2.2	1
895	Brain gene therapy with Trojan horse lipid nanoparticles. Trends in Molecular Medicine, 2023, 29, 343-353.	3.5	13
897	Potential of siRNA in COVID-19 therapy: Emphasis on in silico design and nanoparticles based delivery. Frontiers in Bioengineering and Biotechnology, 0, 11, .	2.0	3
899	A third SARS-CoV-2 mRNA vaccine dose in people receiving hemodialysis overcomes B cell defects but elicits a skewed CD4+ TÂcell profile. Cell Reports Medicine, 2023, 4, 100955.	3.3	1
900	Toxicological Assessments of a Pandemic COVID-19 Vaccineâ€"Demonstrating the Suitability of a Platform Approach for mRNA Vaccines. Vaccines, 2023, 11, 417.	2.1	5
901	Single-domain antibody delivery using an mRNA platform protects against lethal doses of botulinum neurotoxin A. Frontiers in Immunology, 0, 14, .	2.2	6
903	Domestic Animals as Potential Reservoirs of Zoonotic Viral Diseases. Annual Review of Animal Biosciences, 2023, 11, 33-55.	3.6	14
904	A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses via Î±-tocopherol component. Frontiers in Immunology, 0, 14, .	2.2	1
905	Meeting Summary: Global Vaccine and Immunization Research Forum, 2021. Vaccine, 2023, 41, 1799-1807.	1.7	5
906	SARS-CoV-2 S Glycoprotein Stabilization Strategies. Viruses, 2023, 15, 558.	1.5	1
907	Study of the Effects of Several SARS-CoV-2 Structural Proteins on Antiviral Immunity. Vaccines, 2023, 11, 524.	2.1	3
908	An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon, 2023, 9, e13952.	1.4	28
909	The quest for an HIV-1 vaccine: will mRNA deliver us from evil?. Expert Review of Vaccines, 2023, 22, 267-269.	2.0	2
910	Application of microfluidic technologies on COVID-19 diagnosis and drug discovery. Acta Pharmaceutica Sinica B, 2023, 13, 2877-2896.	5.7	5
912	Rapid evaluation of heterologous chimeric RBD-dimer mRNA vaccine for currently-epidemic Omicron sub-variants as booster shot after inactivated vaccine. Biosafety and Health, 2023, 5, 89-100.	1.2	4
913	Site of vulnerability on SARS-CoV-2 spike induces broadly protective antibody against antigenically distinct Omicron subvariants. Journal of Clinical Investigation, 2023, 133, .	3.9	4

#	Article	IF	Citations
914	The Function of Memory CD8+ T Cells in Immunotherapy for Human Diseases. Immune Network, 2023, 23, .	1.6	4
915	Effect of SARS-CoV-2 mRNA-Vaccine on the Induction of Myocarditis in Different Murine Animal Models. International Journal of Molecular Sciences, 2023, 24, 5011.	1.8	1
916	Application of nucleic acid-encoded antibodies in prevention and treatment of emerging viral infectious diseases. Chinese Science Bulletin, 2023, , .	0.4	0
917	Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection. Journal of Microbiology, Immunology and Infection, 2023, 56, 516-525.	1.5	3
918	A novel mAb broadly neutralizes SARSâ€CoVâ€2 VOCs in vitro and in vivo, including the Omicron variants. Journal of Medical Virology, 2023, 95, .	2.5	1
919	Advanced Therapies for Patients with COVID-19. , 2023, , 77-92.		0
920	The diversity of the glycan shield of sarbecoviruses related to SARS-CoV-2. Cell Reports, 2023, 42, 112307.	2.9	7
921	mRNA therapeutics: New vaccination and beyond. Fundamental Research, 2023, 3, 749-759.	1.6	6
922	Structural basis for antibody recognition of vulnerable epitopes on Nipah virus F protein. Nature Communications, 2023, 14, .	5.8	5
923	Plant-Derived Extracellular Vesicles as a Delivery Platform for RNA-Based Vaccine: Feasibility Study of an Oral and Intranasal SARS-CoV-2 Vaccine. Pharmaceutics, 2023, 15, 974.	2.0	10
924	Heterologous Vectorâ€”mRNA Based SARS-CoV-2 Vaccination Strategy Appears Superior to a Homologous Vectorâ€”Based Vaccination Scheme in German Healthcare Workers Regarding Humoral SARS-CoV-2 Response Indicating a High Boosting Effect by mRNA Vaccines. Vaccines, 2023, 11, 701.	2.1	3
925	A Possible Blue Print of Addressing mRNA Vaccine Efficacy. , 0, 36, 1433-1438.		0
926	Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine. Frontiers in Immunology, 0, 14, .	2.2	1
927	Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. Cell Reports, 2023, 42, 112326.	2.9	13
928	Pre-clinical models to define correlates of protection for SARS-CoV-2. Frontiers in Immunology, 0, 14, .	2.2	3
929	A new H9 influenza virus mRNA vaccine elicits robust protective immunity against infection. Vaccine, 2023, 41, 2905-2913.	1.7	4
930	Fc-Î³R-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2. Nature Microbiology, 2023, 8, 569-580.	5.9	33
932	A fluorinated ionizable lipid improves the mRNA delivery efficiency of lipid nanoparticles. Journal of Materials Chemistry B, 2023, 11, 4171-4180.	2.9	6

#	Article	IF	Citations
933	A SARS-CoV-2 Vaccine Designed for Manufacturability Results in Unexpected Potency and Non-Waning Humoral Response. Vaccines, 2023, 11, 832.	2.1	1
934	Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations. International Journal of Molecular Sciences, 2023, 24, 7292.	1.8	2
935	Does the SARS-CoV-2 spike really have an Achilles heel?. Journal of Clinical Investigation, 2023, 133, .	3.9	0
936	A replicon RNA vaccine can induce durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned. PLoS Pathogens, 2023, 19, e1011298.	2.1	5
937	ESCRT recruitment to SARS-CoV-2 spike induces virus-like particles that improve mRNA vaccines. Cell, 2023, 186, 2380-2391.e9.	13.5	9
938	Cholera toxin B scaffolded, focused SIV V2 epitope elicits antibodies that influence the risk of SIVmac251 acquisition in macaques. Frontiers in Immunology, 0, 14, .	2.2	0
943	mRNA Vaccine Platform: mRNA Production and Delivery. Russian Journal of Bioorganic Chemistry, 2023, 49, 220-235.	0.3	1
944	Nucleic Acid Therapeutics. , 2022, , 350-402.		0
964	Deoxyestrone-based lipofection agents with solution- and solid-state emission properties. Organic and Biomolecular Chemistry, 0, , .	1.5	0
968	Incorporating the Molecular Mimicry of Environmental Antigens into the Causality of Autoimmune Hepatitis. Digestive Diseases and Sciences, 2023, 68, 2824-2842.	1.1	4
972	Regulation and functions of non-m6A mRNA modifications. Nature Reviews Molecular Cell Biology, 2023, 24, 714-731.	16.1	25
979	Zika Virus Vaccines. , 2023, , 1322-1333.e7.		0
999	mRNA vaccines in disease prevention and treatment. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	9
1007	Circular RNA vaccine in disease prevention and treatment. Signal Transduction and Targeted Therapy, 2023, 8, .	7.1	3
1022	RNA Nanomedicine: Delivery Strategies and Applications. AAPS Journal, 2023, 25, .	2.2	1
1034	Advanced Formulation Approaches for Emerging Therapeutic Technologies. Handbook of Experimental Pharmacology, 2023, , .	0.9	0
1050	(Re-)emerging viral zoonotic diseases at the humanâ€“animalâ€“environment interface. , 2024, , 93-111.		0
1079	Coagulation and Thrombotic Considerations in Covid-19: Implications for Disease Severity, and Its Vaccines. , 2023, , .		0

#	Article	IF	Citations
1082	3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA. Lab on A Chip, 2024, 24, 162-170.	3.1	1
1087	Introductory Chapter: Current Landscape of Animal and Human Virus Treatments. Infectious Diseases, 0, , .	4.0	0
1096	Therapeutic synthetic and natural materials for immunoengineering. Chemical Society Reviews, 2024, 53, 1789-1822.	18.7	0
1109	Molecular medical microbiologyâ€"from bench to bedside. , 2024, , 1-6.		0
1110	Genetic modification of mice using CRISPR-Cas9: Best practices and practical concepts explained. , 2024, , 425-452.		0
1113	Circular RNAs: Regulators of endothelial cell dysfunction in atherosclerosis. Journal of Molecular Medicine, 2024, 102, 313-335.	1.7	0
1118	RNA therapeutics for infectious diseases. Progress in Molecular Biology and Translational Science, 2024, , 109-132.	0.9	0